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ASPECTS OF CAUSAL INFERENCE 
John A. Craycroft 
December 12, 2020 
Observational studies differ from experimental studies in that assignment of 
subjects to treatments is not randomized but rather occurs due to natural mechanisms, 
which are usually hidden from researchers. Yet objectives of the two studies are frequently 
the same: identify the causal – rather than merely associational – relationship between some 
treatment or exposure and an outcome. The statistical issues that arise in properly analyzing 
observational data for this goal are numerous and fascinating, and these issues are 
encompassed in the domain of causal inference. The research presented in this dissertation 
explores several distinct aspects of causal inference. 
 This dissertation is divided into four chapters. Chapter One gives an introduction 
to major concepts, underlying assumptions, and analytical frameworks encountered in the 
domain of causal inference. The next three chapters describe extensive research projects 
that are linked together by those threads. 
Chapter Two deals with propensity score techniques and, more specifically, how to 
specify the propensity score model to achieve the best treatment effect estimates. This 
chapter not only provides a theoretical proof showing that one particular type of 
specification is best, but also demonstrates an original method for applying that result. The 
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method presented in Chapter Three has a similar purpose – obtaining precise and accurate 
estimates of causal effects – but views the challenge through a Bayesian, rather than a 
frequentist, lens. Here, a hierarchical Bayesian model is developed that is grounded in the 
framework of causal inference. 
 While Chapters Two and Three focus on scenarios involving causal inference from 
observational data, Chapter Four presents a method that has been designed to apply equally 
well to experimental data. The intent of the research here is to provide a method for 
identifying subgroups of the population in which the treatment effect differs from the 
overall population average treatment effect. Maintaining a central theme of causal 
inference, the research focuses on avoiding confounding bias while identifying effect 
modifiers that characterize the subgroups. 
In all, this dissertation is intended to provide views of causal inference concepts 
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1.1  Potential outcomes and causal inference 
 Causal inference in statistics is the process of reasoning from specific samples of 
data to general population-level conclusions regarding causal relationships between some 
treatment or exposure and some outcome or result (Hernán & Robins, 2020). For any given 
study, “treatment/exposure” and “outcome/result” must be precisely defined, but 
conceptually, these terms can carry a broad variety of meanings. The former could refer to 
receiving an experimental drug; carrying a particular gene; participating in a nutritional 
diet; engaging in an educational program; or implementing a tax policy change. The latter 
could refer to some measurement of disease status (cured or not, degree of improvement); 
a specific phenotype; a particular health outcome; a future standardized test score, or future 
earnings; or future tax receipts, employment levels, business closings, or share of votes 
received in the next election. Any pair of concepts, or phenomena, or events that can be 
reasonably precisely defined could, in theory, be studied for their causal relationship with 
each other. 
But what is meant by a “causal” relationship? To elucidate this idea from a 
statistical perspective, we introduce some notation. We will use the symbol T to refer to 
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the treatment/exposure concept, and the symbol Y to refer to the outcome/result concept. 
(Later, these symbols will be used to represent random variables.) What does it mean, then, 
for T to be a cause of Y, or equivalently, for Y to be an effect of T? A helpful framework 
for precisely defining what is meant by a “causal” relationship is the potential outcomes 
framework (Rubin, 1974). In this system, each study unit is hypothesized to have a number 
of possible outcome values equal to the number of possible treatments that could be 
received. For example, with a binary treatment, say an experimental drug and a placebo 
(and so we might code a random variable as 𝑇 ∈ {0,1}), each study unit would have two 
potential outcomes. We denote these two parts of Y as 𝑌( ) and 𝑌( ). Necessarily, only one 
of the potential outcomes is actually observed, specifically that one corresponding to the 
treatment level the study unit actually received. The other potential outcomes are 
unobserved, counterfactual (Lewis, 1973) values. While this example as well as the three 
methods described in this dissertation all focus on scenarios with binary treatments, the 
potential outcomes concept extends generally to non-binary treatment scenarios as well. 
To say that there is a causal relationship between T and Y means that the individual 
potential outcome values of Y differ in some way. The causal effect of T on Y refers to the 
magnitude and nature of the variations among the potential outcomes. Subject-level causal 
effects are computed by comparing the potential outcomes for that subject under each 
treatment level. Since only one potential outcome is observed (the “fundamental problem 
of causal inference” (Holland, 1986)), subject-level causal effects are never known. 
However, population-level causal effects may be estimated if the treatment groups are, on 
average, comparable. For the groups to be comparable requires a variety of assumptions, 
and those assumptions are met in different ways in the context of randomized controlled 
3 
 
experiments and observational studies; these assumptions are described in more detail in 
Section 1.3. In the next section, we discuss measures of causal effect. 
 
1.2 Measures of causal effect 
 There are two dimensions to consider when thinking about measuring causal effect. 
The first dimension is the level at which subject-level causal effects are aggregated. As 
mentioned above, we can never know subject-level causal effects, because we can’t 
observe more than one potential outcome per subject. Hence, we are always considering 
average effects over some group. But what group? One intuitive answer is that we want to 
compare the average response under treatment to the average response under control for 
the entire target population; we term this the average treatment effect (ATE). A second 
answer, at times more appropriate than the ATE, is that we want to know the average 
response for those in the treatment group only compared to those same subjects. For this 
objective we use the average treatment effect among the treated (ATT). As an example, 
suppose we want to know the effect of a blood pressure medication in terms of magnitude 
of blood pressure reduction. Let us assume what is likely the case, that the medication has 
a higher effect on individuals who already have high blood pressure. Then if we average 
the treatment effect over all individuals, the apparent average effect will be lower than if 
we had averaged the treatment effect only over those individuals who already had high 




The second dimension to consider when measuring causal effect is which type of 
measurement of association is most meaningful. The risk difference, risk ratio, and odds 
ratio are three different measures that, depending on circumstances, may be more or less 
appropriate for one’s intended research purpose. In the work presented in this dissertation, 
the focus is always on the risk difference. Hence we define the average treatment effect as: 
𝐴𝑇𝐸 = 𝐸 𝑌( ) − 𝐸[𝑌( )]. 
 
1.3 Assumptions required for valid causal inference 
Several assumptions must hold true for causal inference to be valid (Hernán & 
Robins, 2020). First, exchangeability of the treated and untreated subjects means that the 
potential outcomes are independent of the treatment group, conditional on the covariates. 
That is, 𝑌( ) ⊥ 𝑇|𝑿. The second assumption that must hold is positivity, which means that 
every subject must have some chance of appearing in both the treatment group and the 
control group, i.e., 0 < 𝑝 (𝑿 ) < 1, for all 𝑖, where 𝑝 (𝑿 ) = Pr(𝑇 = 1|𝑿 ). The third 
assumption is consistency; this simply means that the observed outcome matches the 
potential outcome for each subject: (𝑌 |𝑇 = 𝑡) = 𝑌( ), for all 𝑖. 
 
1.4 Structure of this dissertation 
 After this introductory chapter, we present three distinct methods relating to various 
aspects of causal inference. Chapter Two deals with propensity score techniques and, more 
specifically, how to specify the propensity score model to achieve the best treatment effect 
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estimates. This chapter not only provides a theoretical proof showing that one particular 
type of specification is best, but also demonstrates an original method for applying that 
result. The method presented in Chapter Three has a similar purpose – obtaining precise 
and accurate estimates of causal effects – but views the challenge through a Bayesian, 
rather than a frequentist, lens. Here, a hierarchical Bayesian model is developed that is 
grounded in the framework of causal inference. Chapter Four presents a method for 
identifying subgroups of the population in which the treatment effect differs from the 
overall population average treatment effect. Maintaining a central theme of causal 
inference, the research focuses on avoiding confounding bias while identifying effect 






PROPENSITY SCORE SPECIFICATION FOR OPTIMAL ESTIMATION 
OF AVERAGE TREATMENT EFFECT WITH BINARY RESPONSE1 
 
2.1 Introduction 
Observational studies are critical for scientific advancement. While randomized 
controlled trials (RCTs) may be considered the gold standard for establishing evidence 
supporting some causal relationship, there are many circumstances in which conducting an 
RCT is impractical, unfeasible, unethical, or impossible. Meanwhile, observational data 
abound, and it is quite natural to look to it for scientific insights. Yet countless examples 
demonstrate that a real danger lurks in the careless use of observational data, the fallacy of 
conflating association with causation. 
One class of methods for the causal analysis of observational data is propensity 
score-based methods. Formalized in a landmark paper by Rosenbaum and Rubin (1983), 
these techniques begin with estimating for each subject a propensity score. The propensity 
score serves two roles simultaneously: it is the conditional probability of treatment group 
 
 
1 The material in this chapter has been published in Statistical Methods in Medical Research. The full 
citation is: “Craycroft, J. A., Huang, J., & Kong, M. (2020). Propensity score specification for optimal 




given covariates, and it is also a balancing score, the adjustment for which results in similar 
distributions of covariates for treatment and control groups (Rosenbaum & Rubin, 1983). 
Given the propensity scores, any of a variety of methods may be used to estimate 
the average treatment effect (ATE). Stratification, matching, weighting, and covariate 
adjustment are commonly used methods. Many accessible descriptions and illustrations of 
propensity score methods are available in the literature (Abdia, Kulasekera, Datta, Boakye, 
& Kong, 2017; Austin, 2011; Lunceford & Davidian, 2004; Yan et al., 2019). However, 
regardless of the ATE estimation method, and before the ATE estimates may be computed, 
the propensity scores themselves must be estimated. Typically, logistic regression or some 
nonparametric method, such as gradient boosting (McCaffrey et al., 2013), is used. An 
important question receiving much attention in past research is which of the available 
covariates should be included in the propensity score model to most effectively remove 
confounding bias from, and reduce the variance of, the ATE estimates. There are examples 
in the propensity score literature (Austin, 2011; McCaffrey et al., 2013) suggesting that all 
available covariates are used in estimating the propensity scores, an approach that treats all 
covariates as potential confounding variables to be adjusted for (Figure 2.1a). In reality, 
covariates may be of several types (Figure 2.1b): true confounders (𝑿𝑪), affecting both 
treatment and outcome; instrumental variables (𝑿𝑰), affecting the treatment but not the 
outcome; predictor variables (𝑿𝑷), affecting the outcome but not the treatment; and 
spurious, or noise, variables (𝑿𝑺), affecting neither the treatment nor the outcome. (We use 
bold font for the covariate type labels throughout this paper to indicate that they typically 
refer to vectors of covariates, rather than single covariates.) The identification of individual 
covariates with their particular type is sometimes informed by existing subject matter 
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knowledge, or by prior research. Other times, there is little a priori guidance, and it is the 
analyst’s job to accurately categorize the available covariates. 
 
Figure 2.1. Overly simplistic (a) and more realistic (b) causal diagrams. 
 
For a propensity score estimation method to yield unbiased estimates of ATE, all 
true confounders must be included in the propensity score model (Pearl, 2009) (unless the 
doubly robust ATE estimation method is used, which requires either the propensity score 
model or the outcome model be correctly specified) (Lunceford & Davidian, 2004). Also, 
multiple authors (Austin, 2007; Brookhart et al., 2006; Franklin, Eddings, Glynn, & 
Schneeweiss, 2015; Garrido et al., 2014; Patrick et al., 2011) have demonstrated that 1) 
including predictor variables in the propensity score model, while not needed for unbiased 
estimation of treatment effects, is in general beneficial for improving the precision of 
treatment effect estimates; and 2) including instrumental variables in the propensity score 
model increases the variance of the estimated treatment effect. Finally, including noise 
variables in the propensity score model should not affect bias, but will likely increase 


























Consequently, in employing propensity score methods to estimate treatment 
effects, we are faced with a variable selection problem in which, given a potentially large 
set of covariates, we wish to identify only a particular subset to include in our propensity 
score model – specifically, the true confounders and the predictor variables. The analytical 
benefit of the propensity score derives from its role as a balancing score. When deciding 
which variables belong in the propensity score model, the question to answer is not how 
best to predict treatment group membership, but rather which covariates should be balanced 
in order to obtain the least biased and most precise estimates of treatment effect. 
Two methods have been proposed recently for efficiently estimating propensity 
scores, but each method has its own drawback. Shortreed and Ertefaie (2017) introduced 
the outcome-adaptive lasso (OAL), which is a modification of the adaptive lasso (Zou, 
2006). OAL aims to select true confounders and predictor variables into the propensity 
score estimation model via an adaptive lasso method where the weights in the lasso penalty 
term are the inverse of the estimated coefficients in the outcome regression model. In so 
doing, the OAL method assigns higher penalties to terms that are not related to the outcome 
(i.e., instrumental and spurious covariates) and lower penalties to terms that are related to 
the outcome (i.e., predictors and true confounders). Consequently, the minimization of the 
loss function results in forcing coefficients of instrumental and spurious covariates to zero, 
keeping only the predictors and confounders in the propensity score estimation model, as 
desired. As OAL is a variation of penalized regression, a tuning parameter, 𝜆, controls the 
overall strength of the penalty term. In OAL, 𝜆 is selected so as to minimize the weighted 
absolute mean difference (wAMD) between the two treatment groups. The wAMD is a 
measure of covariate balance. Thus OAL cleverly incorporates both variable selection and 
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covariate balancing. After the propensity scores are thus estimated, any propensity score 
application method may be used to estimate ATE; the authors demonstrate their approach 
using the inverse probability weighting (IPW) method. The drawback to OAL is that, 
because of the initial outcome regression, the model breaks down when 𝑝 > 𝑛. 
Imai and Ratkovic (2014) recently introduced the covariate balancing propensity 
score (CBPS) with the recognition that the most important role of the propensity score is 
to balance the covariates between the treatment groups. The “just-identified” CBPS is 
obtained by using the covariate balance score only, while the “overidentified” CBPS is 
obtained by using both the covariate balance score and the score function. The drawback 
to CBPS is that it balances all covariates, rather than attempting to select only the 𝑿  and 
𝑿  types. 
The objective of the current study is two-fold: first, we provide a theoretical proof 
that the most efficient treatment effect estimates are obtained by specifying the propensity 
score as a function of all covariates related to outcome and excluding covariates related 
only to treatment. Second, we present an approach for estimating propensity scores that 
should mitigate the shortcomings of the OAL and CBPS methods mentioned above. The 
structure of the remainder of the paper is as follows: in Section 2.2, we first provide 
background on the potential outcomes framework, ATE, and causal inference from 
observational data, including assumptions that must hold for valid causal inference. We 
then present a theoretical proof showing why the subset of 𝑿 consisting only of 𝑿  and 𝑿  
in the propensity score model results in the most efficient estimates of ATE. We also 
describe our proposed method for obtaining propensity score estimates. In Section 2.3, we 
describe the extensive simulation studies we conducted to compare several propensity 
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score specification methods. In Section 2.4, we describe the application of the methods to 
a case study dataset with the objective of determining if patients’ preoperative blood 
clotting factor is causally related to 30-day mortality following cardiac surgery. Finally, in 
Section 2.5 we provide discussion of the results and general conclusions. 
 
2.2 Methods 
2.2.1 Potential outcomes and ATE 
A great deal of the causal inference literature works from the potential outcomes 
framework (Little & Rubin, 2000). In this framework, we suppose that every subject in the 
data set has a number of potential outcomes equal to the number of distinct treatment 
groups. Only one of these potential outcomes for each subject is ever actually observed; 
the other is a “counterfactual” outcome. However, we assume that subjects who are very 
similar in as many aspects as possible will have very similar potential outcomes. Hence, 
the ATE may be computed by comparing subjects who are very similar in all aspects except 
their treatment group membership (Holland, 1986). 
This paper focuses on the binary treatment and binary outcome scenario. We use T 
to indicate treatment group and Y to indicate outcome, with 𝑇, 𝑌 ∈ {0,1}. We denote the 
two potential outcomes for subject i, i=1,…,n, as 𝑌( ) and 𝑌( ), corresponding respectively 
to the outcomes for control and treatment. As only one of these is actually observed, the 
observed outcome is 𝑌 = 𝑇 𝑌( ) + (1 − 𝑇 )𝑌( ). The objective is to estimate the ATE, 
which is denoted by 𝜏 and defined as 




The propensity score is defined as the conditional probability of treatment group 
membership, given the subject’s covariates. In notation, 𝑝 (𝑿) = 𝑃(𝑇 = 1|𝑿 ), where 𝑝 
(or 𝑝(𝑿)) represents the propensity score, and 𝑿 represents the set of covariates. In this 
chapter, we use the IPW method to estimate ATE, whereby each unit is weighted by the 
inverse of the probability of the treatment status which that unit actually received. The IPW 









(1 − 𝑇 )𝑌
1 − 𝑝
                                            (1) 
with 𝑇 , 𝑌 ∈ {0,1}. Under the assumptions of exchangeability and positivity, described 
below, this estimator has been shown to be unbiased (Lunceford & Davidian, 2004). 
 
2.2.2 Assumptions required for causal inference 
Several assumptions must hold true for causal inference, whether stemming from 
observational or experimental data, to be justified. First, exchangeability of the treated and 
untreated subjects means that the potential outcomes are independent of the treatment 
group, conditional on the covariates. That is, 𝑌( ) ⊥ 𝑇|𝑿. Pearl (2009) proved that if the 
set 𝑿 includes all true confounders, 𝑿 , then exchangeability holds: 𝑌( ) ⊥ 𝑇|𝑿 . 
Rosenbaum and Rubin (1983) showed that if exchangeability holds given 𝑿, then it also 
holds given the propensity score: 𝑌( ) ⊥ 𝑇|𝑝(𝑿). The second assumption that must hold is 
positivity, which means that every subject must have some chance of appearing in both the 
treatment group and the control group, i.e., 0 < 𝑝 (𝑿 ) < 1, for all 𝑖. The third assumption 
is consistency; this simply means that the observed outcome matches the potential outcome 




2.2.3 Theoretical study for variance reduction of ATE estimator by including 𝑿  and 𝑿  
in propensity score estimation 
Hahn (1998) showed that under exchangeability, the asymptotic variance bound for 







+ (𝜏(𝑿) − 𝜏)  ,                                      (2) 
where 𝜎 (𝑿) = 𝑣𝑎𝑟(𝑌( )|𝑿), 𝜎 (𝑿) = 𝑣𝑎𝑟(𝑌( )|𝑿), and 𝜏(𝑿) = 𝐸 𝑌( ) 𝑿 −
𝐸 𝑌( ) 𝑿 . Hirano et al.(2003), showed that the ATE estimator (1) achieves the lower 
bound (2) under some regularity conditions. In the following, we show that ATE estimates 
with different adjustment sets of pre-treatment covariates are all unbiased; however, the 
ATE estimate with the adjustment set {𝑿 , 𝑿 } is the most efficient, i.e., it has the smallest 
variance. 
 
Proposition 1 (conditional independence) (Hernán & Robins, 2020; Pearl, Glymour, & 
Jewell, 2016): Assume that the variables all follow the directed acyclic graph shown in 
Figure 1b. The set of variables 𝑿  blocks the backdoor path from T to Y, 𝑇 ← 𝑿 → 𝑌. 
This means that if we ignore the direct path from 𝑇 → 𝑌, then the following conditional 
independences given 𝑿  all hold: (i) 𝑇 ⊥ (𝑌( ), 𝑌( ))|𝑿 ; (ii) (𝑿 , 𝑇) ⊥ (𝑌( ), 𝑌( ))|𝑿 ; 




Theorem 1: Under Proposition 1, exchangeability holds given any of the following sets of 
covariates: (i) 𝑿 ; (ii) 𝑿 , 𝑿 ; (iii) 𝑿 , 𝑿 ; or (iv) 𝑿 , 𝑿 , 𝑿 . That is, 𝑇 ⊥ (𝑌( ), 𝑌( ))|𝑿(∗), 
where 𝑿(∗) is any set of covariates (henceforth referred to as “adjustment sets”) specified 
in (i), (ii), (iii), or (iv). Furthermore, assuming positivity holds under each adjustment set, 
the four IPW estimators resulting from applying formula (1) with each adjustment set are 
all unbiased. That is, 
𝐸 ?̂?(∗) = 𝜏                                                                    (3) 
where * indicates one of the four adjustment sets, and ?̂?(∗) has the same expression as (1) 
except that in the denominator, 𝑝  is defined as 𝑃𝑟(𝑇 = 1|𝑿(∗)). It should be highlighted 
that 𝜏 𝑿(∗) = 𝐸 𝑌( ) 𝑿(∗) − 𝐸 𝑌( ) 𝑿(∗) , the conditional treatment effect given one of 
the adjustment sets. Meanwhile, ?̂?(∗) indicates the IPW estimator of ATE in (1) where the 
propensity score model for 𝑝 includes only 𝑿(∗). 
The proof of the exchangeability assumptions and the unbiasedness of (3) stated in 
Theorem 1 is provided in Appendix 1, as is the proof for Theorem 2, below. 
 
Theorem 2: The IPW estimator for the ATE is most efficient when the propensity score 
model includes true confounders 𝑿  and predictors 𝑿  only.  
i.   𝐸
𝜎 (𝑋 , 𝑋 )
𝑝(𝑋 , 𝑋 )
+
𝜎 (𝑋 , 𝑋 )
1 − 𝑝(𝑋 , 𝑋 )
+ (𝜏(𝑋 , 𝑋 ) − 𝜏)  
≤  𝐸
𝜎 (𝑋 , 𝑋 , 𝑋 )
𝑝(𝑋 , 𝑋 , 𝑋 )
+
𝜎 (𝑋 , 𝑋 , 𝑋 )
1 − 𝑝(𝑋 , 𝑋 , 𝑋 )




𝜎 (𝑋 , 𝑋 )
𝑝(𝑋 , 𝑋 )
+
𝜎 (𝑋 , 𝑋 )
1 − 𝑝(𝑋 , 𝑋 )
+ (𝜏(𝑋 , 𝑋 ) − 𝜏)  
Because the ATE estimate ?̂? in Equation (1) achieves the asymptotic variance bound 
specified in Equation (2), the inequalities in (4) imply that 𝑉𝑎𝑟 ?̂?( ) ≤
𝑉𝑎𝑟 ?̂?( ) ≤ 𝑉𝑎𝑟 ?̂?( ) .  
ii.   𝐸
𝜎 (𝑋 , 𝑋 )
𝑝(𝑋 , 𝑋 )
+
𝜎 (𝑋 , 𝑋 )
1 − 𝑝(𝑋 , 𝑋 )
+ (𝜏(𝑋 , 𝑋 ) − 𝜏)  





1 − 𝑝(𝑋 )
+ (𝜏(𝑋 ) − 𝜏)                                                     (5) 
≤   𝐸
𝜎 (𝑋 , 𝑋 )
𝑝(𝑋 , 𝑋 )
+
𝜎 (𝑋 , 𝑋 )
1 − 𝑝(𝑋 , 𝑋 )
+ (𝜏(𝑋 , 𝑋 ) − 𝜏)  
Again, the ATE estimate ?̂? in Equation (1) achieves the asymptotic variance bound 
specified in Equation (2), so the inequalities in (5) imply that 𝑉𝑎𝑟 ?̂?( ) ≤ 𝑉𝑎𝑟 ?̂?( ) ≤
𝑉𝑎𝑟 ?̂?( ) . 
 
2.2.4 Proposed method: variable selection via elastic net 
Theorem 2, along with the literature cited in Section 2.1, demonstrates that the 
propensity score IPW estimator of the ATE is most efficient if the propensity score model 
includes true confounders and predictors only. The proposed method selects these 
covariates by leveraging the elastic net penalized regression procedure. The elastic net, a 
hybrid between ridge regression and lasso regression, was developed to help in situations 
with large p, and for situations in which groups of covariates are correlated with each other 
(Zou & Hastie, 2005). The proposed propensity score estimation method includes two 
16 
 
steps: we first build an elastic net regression model using all available covariates and the 
treatment group indicator as the regressors and the outcome Y as the dependent variable. 
All covariates in this elastic net model that receive a non-zero coefficient are indicated as 
relating to the outcome; hence, all of these variables are considered to be either the true 
confounder or the predictor type, and they are therefore the variables to be included in our 
propensity score model. Next, only those variables selected by the elastic net method in the 
outcome model are sent to either a regular logistic regression (with treatment, 𝑇, as the 
dependent variable) or to the CBPS estimating procedure to estimate propensity scores. 
The resulting estimated propensity scores are then used in whichever propensity score-
based method is desired. (In this chapter we use the IPW method, where the propensity 
scores in (1) are replaced by their estimates; common alternative methods include 
matching, doubly robust regression, and stratification.) Because it leverages the advantage 
of the elastic net, this approach is expected to work effectively even when p > n, thus 
addressing a shortcoming of OAL; this approach should also yield the most precise ATE 
estimates, because covariates related only to treatment and spurious covariates are 
excluded from the propensity score specification. 






𝑙(𝑦 , 𝛽 + 𝜷𝑻𝒙 ) + 𝜆 (1 − 𝛼 )
‖𝜷‖
2
+ 𝛼 ‖𝜷‖ , 
where 𝑙(𝑦 , 𝛽 + 𝜷𝑻𝒙 ) is the negative log-likelihood contribution for observation i (Hastie 
& Qian, 2014). The overall strength of the penalty is controlled by the tuning parameter 𝜆, 
which is selected via cross-validation. The elastic net penalty is a convex combination of 
the L2-norm ridge penalty (‖𝜷‖ ) and the L1-norm lasso penalty (‖𝜷‖ ), with the relative 
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weighting between the two controlled by the parameter 𝛼 . When 𝛼 = 0, elastic net 
reduces to ridge regression; when 𝛼 = 1, elastic net reduces to lasso. To effectively use 
the elastic net method, we consider both 𝛼  and 𝜆 as tuning parameters. In our proposed 
method, the best value for 𝛼  for a particular dataset is determined by performing the 
elastic net outcome regression under a variety of 𝛼  settings (𝛼 ∈ [0, 1]), and then 
selecting that value that results in the model with the lowest cross-validation error. It is the 
covariates selected by this particular elastic net model, then, that are sent to a logistic 
regression or to the CBPS algorithm for estimation of the propensity scores. We refer to 
this approach as the “EN-optimal” method in our simulation study and case study. 
Note that the drawback of OAL is that it will break down in situations with large p 
relative to n, because the regression step for the outcome model will not converge. CBPS 
makes no variable selection, but rather balances all the available covariates. The proposed 
method addresses both of these drawbacks. 
 
2.3 Simulation 
We conducted simulation studies to explore the properties of the proposed method 
and to compare operating characteristics among alternative methods. Our simulations 
examined the effects of sample size, number of measured covariates, correlation between 
covariates of the same type, strengths of associations between covariates and treatment, 
and strengths of associations between covariates and outcome, following the general 





2.3.1 Simulation procedure 
The data generating process consisted of the following steps:   
1. Generate an 𝑛 × 𝑝 design matrix of Gaussian-distributed covariates, with two 
columns each of confounders, instrumental variables, and predictor variables, and 
𝑝 − 6 columns of spurious covariates. We represent a vector of covariates for one 
observation as 𝑿 = 𝑋 , 𝑋 , 𝑋 , 𝑋 , 𝑋 , 𝑋 , 𝑋 , 𝑋 , … , 𝑋 ( ) . The spurious 
covariates were always mutually independent. For the other three covariate types, we 
tested different correlation coefficients, and the correlations were imposed within 
each type. Simulation settings at this step included sample size (𝑛 ∈ {500, 1000}), 
correlation coefficients ((𝜌 , 𝜌 , 𝜌 ) ∈ {(0, 0, 0); (0.2, 0.2, 0.2); (0.5, 0.5, 0.5)}), and 
number of covariates (𝑝 ∈ {20, 100, 600}). 
2. Generate n observations of the treatment, 𝑇 ∈ {0,1}, as a binomial random variable 
with 𝑃(𝑇 = 1|𝑿) obtained from the underlying model 𝑙𝑜𝑔𝑖𝑡[𝑃(𝑇 = 1|𝑿)] = 𝛽 +
𝛽 𝑋 + 𝛽 𝑋 + 𝛽 𝑋 + 𝛽 𝑋 . Simulation settings at this step included the vector 
of 𝛽 values, controlling the strength of the associations between confounders and 
treatment (𝛽 ), and between instrumental variables and treatment (𝛽 ), where 𝛽 , 𝛽 ∈
{0.6, 1.0, 1.6} for low, medium, or high association strengths. 
3. Generate n observations of the outcome, 𝑌 ∈ {0,1}, as a binomial random variable 
with 𝑃(𝑌 = 1|𝑿, 𝑇) obtained from the underlying model 𝑙𝑜𝑔𝑖𝑡[𝑃(𝑌 = 1|𝑿, 𝑇)] =
𝛼 + 𝛼 𝑋 + 𝛼 𝑋 + 𝛼 𝑋 + 𝛼 𝑋 + 𝜏𝑇. Simulation settings at this step 
included the vector of 𝛼 values, controlling the strength of the associations between 
confounders and outcome (𝛼 ), and between predictor variables and outcome (𝛼 ), 
where 𝛼 , 𝛼 ∈ {0.6, 1.0, 1.6} for low, medium, or high association strengths. 𝜏, the 
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coefficient for T in the underlying model, controls the true ATE (risk difference) and 
is set to 0 for comparing operating characteristics of the methodologies. 
The intercept for each model (𝛼  𝑎𝑛𝑑 𝛽 ) was set to log(0.25) to obtain a prevalence of 
treatment and outcome of approximately 𝑒𝑥𝑝𝑖𝑡(log(0.25)) = 0.2. This represents a 
situation where both treatment and outcome are not rare in the population. The strengths 
of associations between the various covariates and the outcome and the treatment comprise 
four individual factors (𝛼 , 𝛼 , 𝛽 , 𝛽 , corresponding to the 4 solid arrows in Figure 2.1b), 
each with three possible settings (low, medium, or high), yielding 3 = 81 distinct settings 
for covariate association strengths. In our results presented below, we focus on four of 
these, which are defined in Table 2.1 and labeled as Models A through D. The first column 
of Table 2.1 shows the causal structure for each of the four models, and the arrow weights 
indicate the strengths of associations among covariates. 
Table 2.1: Parameter values for simulation models varying covariate-treatment & 
covariate-outcome associations. 
 
Relationship with Treatment (T) Relationship with Outcome (Y)
MODEL Instrumental variables True confounders True confounders Predictors
A:
Medium Medium Medium Medium
B:
Medium Medium High Low
C:
High Medium Low Low
D:
Low Low Medium High
Key: Arrow weights indicate strength of association Low: Medium: High:
Note: Low/Medium/High settings correspond to parameter values 0.6/1.0/1.6, respectively.





𝛽 = 1 𝛼 = 1 𝛼 = 1
𝛽 = 1 𝛼 = 1.6 𝛼 = 0.6
𝛽 = 1 𝛼 = 0.6 𝛼 = 0.6















Combining all four sets of simulation settings (sample size, number of covariates, 
correlation among covariates, and association strengths) yields 2x3x3x81=1458 possible 
combinations of settings. We chose a selection of settings to explore the general patterns 
for how the methodologies behaved. For each set of parameter settings, we generated 1000 
Monte Carlo datasets, each with 100 bootstrap repetitions for estimating the standard error 
of the ATE estimators. For each dataset, we estimated the ATE using the IPW method. 
These estimations were made under 20 propensity score specification methods, as follows: 
i. The first 10 methods employed elastic net to select covariates related to the 
outcome. We tested nine different settings for 𝛼 : 0.0, 0.1, 0.3, 0.5, 0.6, 0.7, 0.8, 
0.9, and 1.0. Four of these are shown in Table 2.2 and are labeled as EN0, EN0.5, 
EN0.7, and EN1. We also included an “EN-optimal” method (EN.opt in Table 2.2), 
which, for each Monte Carlo dataset, chose the 𝛼  setting (out of the nine just 
listed) yielding the model with the lowest cross-validation error. For each of these 
ten methods, then, the covariates receiving non-zero coefficients were sent to a 
logistic regression model with treatment status as the dependent variable, and the 
estimated propensity scores were the predicted values obtained from the logistic 
regression models. 
ii. The outcome-adaptive lasso method (OAL). 
iii. “Overidentified” and “just-identified” CBPS using all available covariates (Table 
2.2, columns CB.over and CB.just); and “overidentified” and “just-identified” 
CBPS using only covariates selected by the EN.optimal method (Table 2.2, 
columns EN.CB.o and EN.CB.j). 
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iv. Five reference models using the known sets of covariates:  true confounders only 
(Table 2.2, column 𝑿𝑪); confounders and predictors, i.e., the target set (column 
𝑿𝑪𝑿𝑷); confounders and instrumental variables (column 𝑿𝑪𝑿𝑰); confounders, 
predictors, and instrumental variables (column 𝑿𝑪𝑿𝑷𝑿𝑰); and all available 
covariates (column 𝑿𝑪𝑿𝑷𝑿𝑰𝑿𝑺). 
Note that EN0 (ridge regression) is exactly the same as the 𝑿𝑪𝑿𝑷𝑿𝑰𝑿𝑺 reference group. 
The elastic net method is being used here solely for choosing covariates to include in the 
propensity score model, not directly for predicted values; since ridge regression (EN0) does 
no subset selection, all available covariates are always included in the propensity score 
logistic regression model. Table 2.2 presents the bias, standard error, and root mean 
squared error (RMSE) of the ATE estimates for the different scenarios and the various 
propensity score specification methods. 
In this simulation study we were interested in examining how the methods would 
perform in cases with high and low ratios of sample size to total number of parameters. 
Also, for parameter values in the treatment and outcome models, we roughly followed 
settings used in some similar prior simulation studies (Shortreed & Ertefaie, 2017), mainly 
focusing on having enough difference between “high,” “medium,” and “low” strength 
settings such that any performance differences between the tested methods due to this 
factor would be apparent. All simulations and analyses were performed in R 3.2.1 (OAL) 
or R 3.5.2 (all others) (R Core Team, 2018). The CBPS package (Ratkovic, Imai, & Fong, 
2012) was used for all CBPS estimates, and the glmnet package (Hastie & Qian, 2014) was 
used for all elastic net estimates. For OAL, the authors’ provided R code was used 
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(supplementary materials included with the online version of (Shortreed & Ertefaie, 2017)), 
with adaptation for the binary response scenario considered here. 
 
2.3.2 Simulation results 
We highlight below a selection of results to illustrate the major takeaways from the 
study. Table 2.2 summarizes seven different simulation scenarios, with each scenario being 
defined according to the strengths of the associations between the covariates and the 
treatment, the strengths of the associations between the covariates and outcome, the 
correlations among the simulated covariates, and the n/p ratio. For each scenario, Table 2.2 
shows the bias, standard error, and RMSE for the estimated ATE (?̂?) under 15 different 
specifications of the propensity score. Five of those propensity score specifications are 
reference models using known sets of covariates, while the other eleven are tested models. 
The results in Table 2.2 are for the fully independent set of covariates (i.e., 𝜌 = 𝜌 = 𝜌 =
0), and the boxplots of the corresponding ATE estimates are presented in Figure A2.1 in 
Appendix 2. Results for scenarios with correlated covariates with 𝜌 = 𝜌 = 𝜌 = 0.2 and 
0.5 are presented, respectively, in Tables A2.1 and A2.2, as well as in Figures A2.2 and 
A2.3 in Appendix 2; in those scenarios, the relative performances of the various methods 
are consistent with the results shown below. 
Examining only the five reference models (last five columns in Table 2.2), the 
𝑿 𝑿  specification has the lowest RMSE for each scenario. This demonstrates the 
statements made in Section 2.1, and for which we showed a proof in Section 2.2.3. In some 
scenarios, the improvement over the 𝑿  model from including 𝑿  is substantial, while in 
other scenarios it is only slight. Moreover, in every scenario, by comparing columns 𝑿  
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and 𝑿 𝑿 , or columns 𝑿 𝑿  and 𝑿 𝑿 𝑿  in Table 2.2, it is clear that including 𝑿  
increases the variance of the ATE estimates. In general, we conclude the following: (i) all 
ATE estimates are unbiased when all true confounders (𝑿𝑪) are included in the propensity 
score model; (ii) the standard error and RMSE of ATE estimates are lowest when the 
propensity score model uses confounders and predictors (𝑿 𝑿 ) only; (iii) the standard 
error and RMSE of ATE estimates increase when the propensity score model includes the 
instrumental variables (𝑿 ); and (iv) including noise variables in the propensity score 
model further increases the standard error and RMSE of the ATE estimates (column 
𝑿 𝑿 𝑿 𝑿 ). The results in column 𝑿 𝑿  provide benchmarks for comparison with the 
tested models. 
We pointed out that CBPS balances all available covariates. An examination of 
columns CB.over and CB.just relative to other columns in Table 2.2 demonstrates that, 
although they are improvements over the logistic regression model with all covariates 
(columns EN.0 and 𝑿 𝑿 𝑿 𝑿 , which are equivalent), CB.over and CB.just are the worst, 
or very nearly worst, of all the tested specifications. However, when the CBPS approach 
uses only the variables selected via the EN.optimal method (columns EN.CB.o and 
EN.CB.j), the CBPS performance is improved, and the just-identified CBPS is competitive 
with OAL and elastic net specifications (columns EN0.5, EN0.7, EN1, EN.opt and OAL). 
The first five columns in Table 2.2 show that, as the tuning parameter 𝛼  grows 
larger, bias typically stays unchanged, but the variance of the ATE estimates decreases 
(though not necessarily monotonically). This demonstrates that the regularized regression 
penalty is resulting in regression coefficients for covariates unrelated to Y being shrunk to 
zero as the weighting between the lasso penalty and the ridge penalty increasingly favors 
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lasso. The performance under lasso (EN1) and EN.optimal (EN.opt) is competitive with 
the target model (𝑿 𝑿 ). 
Comparing Scenario 3 (n/p = 5) to Scenario 1 (n/p = 50), or Scenario 5 (n/p = 10) 
to Scenario 4 (n/p = 50), we see that the ratio 
(𝑿𝑪𝑿𝑷𝑿𝑰𝑿𝑺)
(𝑿𝑪𝑿𝑷)
 is higher for the cases with 
the lower n/p ratio (scenarios 3 and 5). In other words, the detriment to the ATE estimates 
of failing to do variable selection is higher in models with higher proportions of spurious 
and instrumental variables. Moreover, as seen in Scenario 2, where n/p < 1 (i.e., p > n), we 
cannot obtain results for OAL or for CB.over or CB.just. In this scenario, performing 
variable selection ahead of time via elastic net successfully excludes spurious and 
instrumental variables and results in ATE estimates with bias, standard error, and RMSE 
very close to those of the target (𝑿 𝑿 ) specification. 
 
 





# SCENARIO EN0 EN0.5 EN0.7 EN1 EN.opt OAL CB.over CB.just EN.CB.o EN.CB.j XC X C X P XCXI XCXPXI XCXPXIXS
Model A: Bias 0.001 0.002 0.002 0.002 0.002 0.004 0.027 -0.007 0.015 -0.004 0.002 0.001 0.002 0.002 0.001
1 SE 0.060 0.032 0.031 0.030 0.035 0.033 0.042 0.048 0.032 0.034 0.032 0.029 0.059 0.057 0.060
n/p=50 RMSE 0.060 0.032 0.031 0.030 0.035 0.033 0.050 0.049 0.036 0.034 0.032 0.029 0.059 0.057 0.060
Model A: Bias * 0.006 0.004 0.003 0.005 * * * 0.035 -0.003 0.006 0.004 0.012 0.010 *
2 SE * 0.045 0.044 0.045 0.044 * * * 0.043 0.042 0.051 0.044 0.082 0.079 *
n/p=0.833 RMSE * 0.045 0.044 0.045 0.045 * * * 0.055 0.042 0.051 0.044 0.083 0.079 *
Model A: Bias -0.007 0.005 0.004 0.004 0.004 -0.005 0.075 0.042 0.026 -0.004 0.003 0.002 0.010 0.011 -0.007
3 SE 0.179 0.045 0.042 0.041 0.043 0.039 0.060 0.063 0.041 0.043 0.045 0.041 0.081 0.079 0.179
n/p=5 RMSE 0.179 0.045 0.043 0.042 0.043 0.040 0.095 0.076 0.049 0.043 0.045 0.041 0.082 0.080 0.179
Model B: Bias 0.004 0.006 0.004 0.003 0.004 0.006 0.043 -0.010 0.026 -0.006 0.003 0.003 0.004 0.004 0.004
4 SE 0.059 0.032 0.029 0.026 0.031 0.030 0.040 0.045 0.029 0.032 0.026 0.025 0.055 0.054 0.059
n/p=50 RMSE 0.059 0.032 0.029 0.026 0.031 0.031 0.059 0.046 0.039 0.032 0.026 0.025 0.055 0.055 0.059
Model B: Bias -0.008 0.005 0.003 0.003 0.003 0.007 0.087 -0.009 0.026 -0.008 0.003 0.003 0.006 0.006 -0.008
5 SE 0.083 0.030 0.028 0.027 0.028 0.031 0.038 0.046 0.030 0.031 0.028 0.027 0.055 0.054 0.083
n/p=10 RMSE 0.084 0.030 0.028 0.027 0.028 0.031 0.095 0.047 0.040 0.032 0.028 0.027 0.055 0.055 0.084
Model C: Bias 0.013 0.003 0.003 0.002 0.004 0.008 0.026 -0.002 0.015 0.001 0.001 0.001 0.013 0.013 0.013
6 SE 0.123 0.041 0.040 0.041 0.046 0.051 0.078 0.090 0.043 0.045 0.042 0.040 0.114 0.112 0.123
n/p=25 RMSE 0.124 0.041 0.040 0.041 0.046 0.052 0.082 0.090 0.046 0.045 0.042 0.040 0.114 0.113 0.124
Model D: Bias 0.004 0.001 0.000 0.000 0.001 0.003 0.024 -0.001 0.015 -0.002 -0.001 0.000 0.002 0.004 0.004
7 SE 0.064 0.043 0.042 0.041 0.044 0.044 0.047 0.051 0.041 0.041 0.048 0.041 0.062 0.056 0.064
n/p=25 RMSE 0.064 0.043 0.042 0.041 0.044 0.045 0.053 0.051 0.044 0.041 0.048 0.041 0.062 0.056 0.064
Notes:  EN=Elastic Net (displayed settings include       =0, 0.5, 0.7, 1, and EN.optimal); OAL=Outcome-adaptive Lasso; CB=Covariate Balancing Propensity Score;
 EN.CB=CBPS after Elastic Net (either over- or just-identified).
SE=Standard Error; RMSE=Root Mean Squared Error.
* indicates estimates not available, unable to use propensity score specification since p > n.
Models are defined by strengths of associations between covariates and treatment/outcome. See Figure 1b and Table 1.
Scenarios are defined by Model and n/p ratio.
EN0 is equivalent to X C X P X I X S ; these both use all available covariates in estimating the propensity scores.
X C X P  is “Target” propensity score specification and is emphasized in italics.






The importance of conducting variable selection for the propensity score 
specification also varies according to the  strength of the associations between covariates 
and treatment, and between covariates and outcome. When the associations between 
covariates and the outcome are weak, as in Scenario 6, including all covariates in the 
propensity score specification results in ATE estimates with relatively high bias. This is 
consistent with Brookhart et al. (2006); Austin, Grootendorst, and Anderson (2007); 
Patrick et al. (2011); and Zhu, Schonbach, Coffman, and Williams (2015), among others. 
Meanwhile, when the associations between covariates and treatment are weak, as in 
Scenario 7, there is not much cost in terms of bias for using all covariates in the propensity 
score specification. Nevertheless, there remains a cost in terms of precision; the standard 
error of the estimated ATE in Scenario 7 decreases by about one-third for the target 𝑿 𝑿  
model relative to the 𝑿 𝑿 𝑿 𝑿  model. The lasso (EN1) and the just-identified CBPS after 
elastic net (EN.CB.just) are the most effective here in attaining minimum RMSE. Note that 
the results for Scenarios 6 and 7 are very similar as long as variable selection is done via 
some method. Indeed, elastic net shows huge improvement over no variable selection even 
with 𝛼  set as low as 0.1 (not shown). 
 
2.4 Case Study 
2.4.1 Case study background 
We demonstrate the proposed process on an interesting data set involving the 
association of preoperative conditions with 30-day mortality following cardiac surgery. A 
major challenge of perioperative management for cardiac surgery arises from 
intraoperative and postoperative bleeding. Bleeding can occur due to the trauma of surgery, 
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physiologic changes associated with cardiopulmonary bypass, thrombocytopenia, platelet 
defects, fibrinolysis or coagulation factor deficiency. In these surgeries, blood count, 
coagulation studies and blood group determination are regarded as routine preoperative 
investigations in virtually all patients (Cornelissen & Arrowsmith, 2006). Preoperative 
coagulation studies, including baseline international normalized ratio (INR), platelet 
counts, and platelet function tests, are performed in order to identify risk factors and 
optimize hemostasis. Coagulation studies are of special interest because excessive bleeding 
occurs in between 7% and 53% of patients after cardiac surgery, and bleeding related re-
exploration is associated with high in-hospital mortality and morbidity (Biancari, Mikkola, 
Heikkinen, & al., 2012). Studies on whether these preoperative coagulation tests can 
predict clinical outcomes, or whether correcting any negative conditions found would 
improve outcomes, are sparse and controversial.  
The primary objective of the study was to determine if the level of the preoperative 
international normalized ratio (INR), which is a measure of how long it takes blood to clot, 
is causally associated with post-surgery outcomes, particularly 30-day mortality. The 
dataset was obtained from a retrospective review of 1390 patient medical records at Jewish 
Hospital, Louisville, KY. The patients all had cardiac surgeries performed from January 
2008 to December 2013. The hospital data were linked with the Society of Thoracic 
Surgeons database for additional covariate data. Baseline covariates included age, gender, 
diabetes status, creatinine level,  functional platelet number (i.e., the product of platelet 
count and platelet aggregation percentage), patients’ other health conditions such as 
chronic lung disease, and operative characteristics such as use of an intra-aortic balloon 
pump. This was observational data, as the preoperative level of INR was considered the 
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treatment and was not randomly assigned to units but rather observed as a preoperative 
characteristic of each subject. The data indicated each subject as being in a high INR group 
or a low INR group. It was expected that high INR should be causally associated with a 
higher 30-day mortality, as a higher INR value indicates thinner blood that clots less easily. 
 
2.4.2 Case study results 
Table 2.3 presents the baseline distributions of all covariates in the case study data, 
stratified by treatment and outcome. The 1390 observations were divided nearly equally 
(51% to 49%)  between low INR and high INR groups. 31 (2.2%) of the patients died 
within 30 days post-surgery; of these, 26 (84%) were in the high INR group. Therefore, the 
crude (unadjusted) estimate of the risk difference for 30-day mortality between the high 
and low INR groups was 
𝑃𝑟(𝐷𝑖𝑒𝑑 |𝐻𝑖𝑔ℎ 𝐼𝑁𝑅 𝑔𝑟𝑝) − 𝑃𝑟(𝐷𝑖𝑒𝑑 |𝐿𝑜𝑤 𝐼𝑁𝑅 𝑔𝑟𝑝) = 
− = 0.038 − 0.007 = 0.031, 
with a 95% confidence interval for the estimated risk difference of (0.015, 0.047). A chi-
square test of independence between treatment and outcome was statistically significant 
(Χ =15.2, p-value < 0.001). 
However, this was observational data, and consequently, there was risk of the high 
and low INR groups differing in systematic ways, resulting in confounding bias in the 
estimated risk difference. Indeed, as may be seen in Table 2.3, several covariates appeared 
unequally distributed in the two INR groups (chronic lung disease, diabetes, incidence, 
intra-aortic balloon pump, hypertension, congestive heart failure, and type of surgery). Of 
these, chronic lung disease, incidence, intra-aortic balloon pump, hypertension, congestive 
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heart failure, and type of surgery also appeared to be related to outcome, making these six 
variables candidates for true confounders (XC). Three other variables (gender, peripheral 
vascular disease, and myocardial infarction) also appeared related to 30-day mortality 
(outcome), but not to INR group (treatment), making these three variables potential 
predictors (XP). 
We used the proposed method to estimate the 30-day mortality ATE between high 
INR and low INR groups. Applying the elastic net method on the outcome model (i.e., 
regressing mortality on all baseline covariates) identified three covariates that were 
associated with the outcome (gender, intra-aortic balloon pump, and type of surgery); 
hence, these three variables were used in a logistic regression with the INR group as the 
dependent variable to compute the estimated propensity score for each patient. The 
propensity score IPW estimator was then used to compute an adjusted ATE estimate, which 
was 0.021 (0.004, 0.039). While still positive, the magnitude of the estimated ATE was 
about one-third lower than the unadjusted estimate. From the prior discussion and analysis 




Table 2.3: Baseline distributions of variables by treatment and outcome. 
 
FPN: Functional Platelet Number; CABG: Coronary Artery Bypass Grafting; INR: Int’l Normalized Ratio 
 
Stratified by Treatment Stratified by 30-Day Mortality
Low INR High INR Survived Died % Mortality
Mean/No. (SD/%) Mean/No. (SD/%) Mean/No. (SD/%) Mean/No. (SD/%)
N 706 (50.8)      684 (49.2)      1359 (97.8)      31 (2.2)        2.2
Age 62.31 (11.62)    64.29 (12.47)    63.14 (12.01)    69.29 (13.69)    
Creatinine Level 1.11 (0.83)      1.23 (0.96)      1.16 (0.89)      1.45 (1.21)      
FPN 181.59 (72.41)    185.36 (87.44)    183.97 (80.28)    160.47 (71.69)    
Ejection Fraction 50.29 (15.22)    44.15 (17.50)    47.28 (16.64)    46.81 (17.69)    
Gender
Female 246 (34.8)      216 (31.6)      442 (32.5)      20 (64.5)      4.3
Male 460 (65.2)      468 (68.4)      917 (67.5)      11 (35.5)      1.2
Chronic Lung Disease
No 494 (70.0)      449 (65.6)      928 (68.3)      15 (48.4)      1.6
Mild 118 (16.7)      122 (17.8)      231 (17.0)      9 (29.0)      3.8
Moderate 63 (8.9)        69 (10.1)      128 (9.4)        4 (12.9)      3.0
Severe 31 (4.4)        44 (6.4)        72 (5.3)        3 (9.7)        4.0
Diabetes
No 449 (63.6)      390 (57.0)      820 (60.3)      19 (61.3)      2.3
Yes 257 (36.4)      294 (43.0)      539 (39.7)      12 (38.7)      2.2
Status
Elective 311 (44.1)      300 (43.9)      598 (44.0)      13 (41.9)      2.1
Urgent 392 (55.5)      376 (55.0)      751 (55.3)      17 (54.8)      2.2
Emergent 3 (0.4)        8 (1.2)        10 (0.7)        1 (3.2)        9.1
Incidence
No 650 (92.1)      580 (84.8)      1206 (88.7)      24 (77.4)      2.0
Yes 56 (7.9)        104 (15.2)      153 (11.3)      7 (22.6)      4.4
Intra-Aortic Balloon Pump
No 670 (94.9)      588 (86.0)      1239 (91.2)      19 (61.3)      1.5
Yes 36 (5.1)        96 (14.0)      120 (8.8)        12 (38.7)      9.1
Peripheral Vascular Disease
No 604 (85.6)      583 (85.2)      1163 (85.6)      24 (77.4)      2.0
Yes 102 (14.4)      101 (14.8)      196 (14.4)      7 (22.6)      3.4
Hypertension
No 76 (10.8)      103 (15.1)      174 (12.8)      5 (16.1)      2.8
Yes 630 (89.2)      581 (84.9)      1185 (87.2)      26 (83.9)      2.1
Myocardial Infarction
No 360 (51.0)      375 (54.8)      716 (52.7)      19 (61.3)      2.6
Yes 346 (49.0)      309 (45.2)      643 (47.3)      12 (38.7)      1.8
Congestive Heart Failure
No 337 (47.7)      237 (34.6)      569 (41.9)      5 (16.1)      0.9
Yes 369 (52.3)      447 (65.4)      790 (58.1)      26 (83.9)      3.2
Type of Surgery
CABG 552 (78.2)      383 (56.0)      927 (68.2)      8 (25.8)      0.9
Others 19 (2.7)        50 (7.3)        65 (4.8)        4 (12.9)      5.8
Valve 64 (9.1)        136 (19.9)      191 (14.1)      9 (29.0)      4.5
Both 71 (10.1)      115 (16.8)      176 (13.0)      10 (32.3)      5.4
High INR
No 706 (100.0)    0 (0.0)        701 (51.6)      5 (16.1)      0.7
































For further comparison, the other methods explored in the simulation study above 
were also used for estimating the propensity scores, with the estimated ATEs subsequently 
computed in each case using IPW. The results of these various approaches at specifying 
the propensity score model are summarized in Figure 2.2. 
 
Figure 2.2: ATE estimates with 95% CIs for different methods for the case study on 30-
day mortality. 95% CI is the bootstrap percentile CI, except for the unadjusted estimate. 
 
From Figure 2.2 it is evident that, after adjusting for important covariates, the ATE 
for being in the high INR group was about 2%, indicating that there was about a 2 
percentage point higher risk of 30-day mortality purely due to higher preoperative INR, as 
compared to lower preoperative INR. We also see in Figure 2.2 that the ATE estimate from 
the propensity score model using all covariates (no variable selection) is less precise than 
the other adjusted estimates, although the difference is not very pronounced for this 
particular data set. The similar performance is most likely due to the fact that the variables 
related to treatment are also related to outcomes, that is, there was no instrumental variables 




2.5 Discussion and conclusion 
We have demonstrated from theory as well as via simulation studies that 
eliminating instrumental variables and including true confounders and predictor variables 
in the propensity score specification is beneficial for reducing variance of the ATE 
estimates. We propose using elastic net regression to select the covariates related to the 
outcome variable Y and then using only the selected variables to estimate propensity 
scores. The simulation study endorses the theoretical results developed in this paper, 
although the simulation study serves more as a proof of concept for the elastic net approach 
rather than a definitive evaluation. Based on this study, even a modest effort at removing 
unassociated covariates from the propensity score model can pay large dividends in terms 
of reducing the variance of the ATE estimates. Using lasso (EN1) to select variables for 
the propensity score model is consistently the best, or among the best, approaches. This is 
due to the lasso’s shrinkage of many/most of the extraneous covariates (XIs and XSs).  
The OAL method is usually very good, but OAL is not an option when 𝑝 >  𝑛. The 
same problem holds with CBPS, whether overidentified or just-identified. The proposed 
method is expected to work when 𝑝 > 𝑛 unless the number of true confounding variables 
and predictors is larger than 𝑛 (i.e., (𝑝 + 𝑝 ) > 𝑛). Usually in an observational study, the 
number of observations is in thousands, and we expect the number of confounding 
variables and predictor variables to be smaller than 𝑛, even while the total number of 
variables could be large (say, (𝑝 + 𝑝 + 𝑝 + 𝑝 ) > 𝑛). In this latter scenario, the 
outcome regression in OAL at stage 1 would suffer, while the proposed method may not. 
When the number of true confounding variables and predictors is larger than 𝑛, the 
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convergence problems that hamper OAL at stage 1 will also pose a problem for this method 
at stage 2, and CBPS would also fail. We also found that for both the overidentified and 
just-identified CBPS methods, the variance of the ATE estimator is relatively high. 
However, in some circumstances, the just-identified CBPS after variable selection via 
elastic net is a very competitive method. 
 
Figure 2.3: Radar chart of RMSE for tested methods, 7 scenarios. Vertex numbers indicate 
simulation scenarios (see Table 2.2). *ATE unestimable in Scenario 2 for OAL, CB.over, 
and CB.just. 
 
The radar chart in Figure 2.3 plots the RMSE for six of the tested propensity score 
specification methods for each of the seven simulation scenarios summarized in Table 2.2. 
From the chart, we can see that CB.over and CB.just always have a RMSE greater than the 
other four methods (except for Scenario 2, for which these two methods and OAL produced 
no estimates, and hence have no RMSE); sometimes, as in scenarios 3, 5, and 6, the excess 
RMSE of these two methods compared to the other methods is substantial. Scenarios 3 and 













OAL CB.over CB.just EN.CB.o EN.CB.j EN1
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importance of the variable selection step here is even higher than cases in which the n/p 
ratio is high. In Scenario 6, we have strong covariate associations with the treatment, so 
again, the importance of doing variable selection to exclude the instrumental variables is 
very high. In Scenario 7, there is strong covariate associations with the outcome, but not 
the treatment; in this case, there is not such a high cost in terms of RMSE (driven mostly 
by the variance of the ATE estimates) for not doing variable selection. Meanwhile, there is 
not a large difference in RMSE among OAL, EN.CB.over, EN.CB.just, and EN1; however, 
EN1 (lasso) does have, in most cases, the minimum RMSE, albeit sometimes by a very 
slight margin. 
One issue occasionally mentioned with respect to propensity score methods is the 
ability to compute the propensity score without any reference to outcome data. For 
example, Rubin (2007) emphasizes that in planning an observational study, the choices for 
variables to be measured should be made without looking at the impact of those variables 
on the outcome. Rubin is concerned with what is sometimes termed “p-value fishing”: 
“rather than the outcome data 𝑌  being ‘not in sight,’ they are used over and over again 
to fit various models, try different transformations, look at results discarding influential 
outliers, etc.” (p. 25). Rubin recommends that the decisions on propensity score variables 
“…should be done without ever looking at any outcome data, and thus without looking at 
any answers about causal effects” (p. 33). We totally agree that “p-value fishing” must be 
avoided. In our proposed approach, we are not looking at all at the impact on the estimated 
causal effect when determining which variables are included in the propensity score model. 
We are simply recognizing that an observational data set is likely to contain variables that 
are unrelated to the outcome and therefore irrelevant for propensity score methods. In 
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addition, the prognostic score, the score summarizing the covariates’ association with 
outcomes, has been used to estimate ATE (Hansen, 2008); (Leacy & Stuart, 2014). Even 
in RCTs, variables known unrelated to outcome are likely to be – and should be –  ignored; 
stratification preceding randomization is usually done based on covariates associated with 
outcome34. Thus, we maintain that the procedure emphasized throughout this article, i.e., 
to specify the propensity score model by using only covariates associated with the outcome 
and excluding covariates only associated with the treatment, is not only acceptable, but 
highly recommended. Empirical results (such as those from the simulation study described 
in Section 2.3, and those in the literature referenced in Section 2.1) and the theoretical 
results (Section 2.2) clearly demonstrate the increased precision available with this 
approach. 
Our study, although involving extensive simulations and a high number of 
parameter settings, does have some limitations. These limitations consequently speak to 
areas where further investigation is warranted. First, both the treatment variable and the 
outcome variable in the simulation had a fairly high prevalence, particularly compared to, 
say, the prevalence of most diseases. A future study should examine the performance of 
the various propensity score specification methods under rare prevalence of outcome, and 
perhaps under rare prevalence of treatment. Second, our simulation setup included 
relatively few XC, XI, and XP covariates (exactly two of each). Perhaps more of these 
covariate types would affect the relative performance of the methods. Nevertheless, this 
study did take into account a large number of parameters and settings, and it could be fairly 







BAYESIAN CAUSAL INFERENCE USING MCMC 
 
3.1 Introduction 
The application of Bayesian methods in the field of causal inference has a long 
history, as exemplified by Donald Rubin’s 1978 article in The Annals of Statistics, 
“Bayesian Inference for Causal Effects: The Role of Randomization.”  Rubin has a career-
long involvement in the field of causal inference, including on the frequentist side, being 
(along with Paul Rosenbaum) one of the two authors of the seminal 1983 Biometrika article 
“The Central Role of the Propensity Score in Observational Studies for Causal Effects.” A 
great contribution made by Rubin to the field of causal inference was his extension of the 
potential outcomes framework, which was originated in 1923 by Jerzy Neyman, from 
randomized experiments to observational studies. The potential outcomes framework is 
today a common structure in which to study causal inference. In this framework, each study 
unit is hypothesized to have a number of possible outcome values corresponding to the 
number of possible treatments that could be received. For example, with a binary treatment, 
say an experimental drug and a placebo, each study unit would have two potential 
outcomes. Necessarily, only one of the potential outcomes is actually observed, specifically 
that one corresponding to the treatment level received. The other potential outcomes are 
unobserved, counterfactual values. Causal inference proceeds in this potential outcomes 
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framework by viewing these unobserved potential outcomes as missing data. Subject-level 
causal effects would be computed by comparing the outcomes under each treatment level. 
Since only one potential outcome is observed (the “fundamental problem of causal 
inference” (Holland, 1986)), subject-level causal effects are never known. However, 
population-level causal effects may be estimated if the treatment groups are, on average, 
comparable. For the groups to be comparable requires a variety of assumptions, and those 
assumptions are met in different ways in the context of randomized controlled experiments 
and observational studies. 
Bayesian strategies enter the analysis typically in two different ways. First, as in 
the articles by Rubin and Keil, et al. (Keil, Daza, Engel, Buckley, & Edwards, 2018), due 
to the formulation of the problem in a way that implies missing data, Bayesian methods 
may be used for calculating the predictive distributions of the unobserved data (the non-
realized potential outcomes) given the observed covariates and observed outcomes. Then, 
the estimation of causal effects takes place by directly comparing the individual level 
causal effects computed via the predictive distributions. A second common application of 
Bayesian methodologies in causal inference is in conducting sensitivity analysis on certain 
underlying assumptions. For example, an important assumption in the analysis of 
observational data for causal effects is that there are no unmeasured confounders. Viewing 
any unmeasured confounders as missing data, McCandless, Gustafson, and Levy (2007) 
use Bayesian inference on a hypothesized latent bias term representing all unmeasured 
confounders and assesses how large such a bias term need be to affect one’s directional 
conclusion regarding the causal estimand. In a separate paper, McCandless, Gustafson, and 
Austin (2009) use Bayesian methods to investigate how much accounting for uncertainty 
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in the estimation of propensity scores can affect the precision of estimated treatment effects 
derived from the use of those scores. 
In the work presented in this chapter, we take a somewhat different tack. Indeed, 
this approach is aimed very directly at the underlying research question: what is the average 
causal effect of a treatment on an outcome. We do not model the posterior predictive 
distributions of unobserved outcomes, as per Rubin, nor do we conduct sensitivity analysis. 
Rather, we directly model the posterior conditional distribution of the causal effect itself. 
In the process, we incorporate uncertainties inherent in propensity score modeling, in order 
to achieve causal effect estimates with accurate precision. 
To achieve these goals, we use a hierarchical Bayesian structure to describe the 
entire information set, which is understood as the full complement of data, including 
treatment, outcome, and covariates. We build the structure in a way that carries intuitive 
causal interpretation and that links with the common frequentist causal constructs such as 
the propensity score and the average treatment effect. We then parameterize the model with 
compellingly reasonable prior distributions; “reasonable” here is applied with respect to 
choices about the distribution families and structures, while the level of informativeness of 
those priors is then controlled by choices about hyperparameters. Bayesian Markov chain 
Monte Carlo sampling is then conducted directly on the posterior distribution of the causal 
estimand. The method shows promise in comparing admirably with the nonparametric 
inverse probability weighting (IPW) estimator that is commonly used in causal inference. 
The structure of the remainder of this chapter is as follows: in Section 3.2, we 
provide background on causal inference for observational data and specify the causal risk 
difference estimand for the IPW method. We also describe a Bayesian hierarchical 
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structure for conceptualizing an observational data set, and we explain the intuition 
underlying our parameterization of the structure. In Section 3.3, we describe the simulation 
study we executed to test the proposed Bayesian methodology and evaluate it against the 
typical frequentist IPW approach. In Section 3.4, we illustrate application of the method to 
a case study data set. Finally, in Section 3.5, we provide further discussion of the results 
and general conclusions. 
 
3.2 Methods 
We are concerned with the inverse probability weighting (IPW) estimator of 
average treatment effect (ATE). The basic estimator, developed on techniques elucidated 









𝑦 (1 − 𝑇 )
(1 − 𝑝 )
 
where 𝑦 , 𝑦 , … , 𝑦  are observed outcome values, 𝑇 , 𝑇 , … , 𝑇  are observed treatment 
indicators, and 𝑝 = Pr (𝑇 = 1|𝑿 ) is the propensity score for each subject. Each 𝑿  is a 
vector of pre-treatment covariates. However, this estimator lacks robustness, a situation 










𝑦 (1 − 𝑇 )
(1 − 𝑝 )
∑
(1 − 𝑇 )
(1 − 𝑝 )
 
as described by Lunceford and Davidian (2004). 
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In this article, we deal with the setting with continuous outcome and binary 
treatment, i.e., 𝑌 ∈ ℝ and 𝑇 ∈ [0,1}. The covariates 𝑿  are considered fixed, but may be 
binary, nominal or continuous. We assume the following conditional distributions for the 
data 𝑌  and 𝑇 : 
𝑌 |𝑇 ~
𝑁𝑜𝑟𝑚𝑎𝑙(𝜃 + 𝜏, 𝑝 𝜎 ), 𝑖𝑓 𝑇 = 1
𝑁𝑜𝑟𝑚𝑎𝑙(𝜃, (1 − 𝑝 )𝜎 ), 𝑖𝑓 𝑇 = 0
 
and 
𝑇 |𝑝 ~𝐵𝑒𝑟𝑛𝑜𝑢𝑙𝑙𝑖(𝑝 ). 
In the above, then, 𝜃 is the expected response for a subject in the control group, and 𝜃 + 𝜏 
is the expected response for a subject in the treatment group. 𝜏 captures the treatment effect 
(it is clear that 𝐸[𝑌 |𝑇 = 1] − 𝐸[𝑌 |𝑇 = 0] = (𝜃 + 𝜏) − 𝜃 = 𝜏). Next, 𝑝 = Pr (𝑇 =
1|𝑿 ) is the propensity score. The scale factor in the variance (𝑝  if 𝑇 = 1 and (1 − 𝑝 ) if 
𝑇 = 0) is closely related to inverse probability weighting, where the weight is  if 𝑇 = 1 
and 
( )
 if 𝑇 = 0. Unlike in the frequentist approach, the weights here are considered to 
have variability and are updated over the posterior sampling. 
Next, we need to specify priors for the parameters. We hypothesize the following 
hierarchical scheme that appears fairly complex at first, yet contains logical motivations 
for each element:  
𝜏~𝑁𝑜𝑟𝑚𝑎𝑙(0, 𝜎 ), 




𝜎 ~𝐼𝑛𝑣. 𝐺𝑎𝑚𝑚𝑎(𝑎, 𝑏). 
These three elements of the prior structure are quite straightforward in Bayesian analysis 
of normally distributed data (Gelman et al., 2013). The hyperparameters 𝜎  and 𝜎  would 
usually be provided large values, resulting in flat, non-informative priors, thus giving 
majority of influence to the data rather than the priors. 
Next, 
𝑝 |𝛼 , 𝜆~𝐵𝑒𝑡𝑎(𝜆𝛼 , 𝜆). 
Because 𝑝  is a probability it must be between 0 and 1, and thus the Beta distribution is a 
natural choice for its prior. The parameterization here results in an expected value of 
𝐸[𝑝 |𝛼 , 𝜆] = = . The expected value is independent of 𝜆. 
Next, 
𝛼 |𝜷, 𝜈 ~𝐿𝑜𝑔𝑛𝑜𝑟𝑚𝑎𝑙(𝒙 𝜷, 𝜈 ), 
𝜷~𝑀𝑢𝑙𝑡𝑖𝑣𝑎𝑟. 𝑁𝑜𝑟𝑚𝑎𝑙 𝟎, Σ , 
𝜈 ~𝐼𝑛𝑣. 𝐺𝑎𝑚𝑚𝑎(𝑐, 𝑑), 
and 
𝜆~𝐺𝑎𝑚𝑚𝑎(𝑓, 𝑔). 
Thus, 𝛼  provides the connection between the covariates 𝒙  and the probability of treatment 
𝑝 , while 𝜆 (along with 𝛼 ) controls the variance of the Beta distribution: if 𝜆 gets very 
large, 𝑉𝑎𝑟(𝑝 ) gets very small, indicating strong knowledge about the Pr(𝑇 = 1|𝑿𝒊). The 
hyperparameters for 𝜈  and 𝜆 are typically given values to result in non-informative priors. 
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𝑇 (𝑦 − 𝜏 − 𝜃)
2𝑝 𝜎
+
(1 − 𝑇 )(𝑦 − 𝜃)
2(1 − 𝑝 )𝜎
𝜎 √2𝜋 ∏ (1 − 𝑝 ) 𝑝
 
It may be shown that the value of ?̂? that optimizes this likelihood function is the same as 
the equation for ?̂? .  given above. This demonstrates that we have formulated our 
Bayesian hierarchical model such that the parameter 𝜏 has a very natural interpretation as 
the average treatment effect, with that estimand understood to be the difference in expected 
values of the outcome under the two treatment levels. 
The benefit achieved from the complexity of this hierarchical structure is, first, that 
we incorporate into the posterior estimation of the treatment effect all of the variability that 
exists in estimating the propensity scores for each subject; and second, that we have an 
extremely flexible model that is capable of providing posterior estimates of the treatment 
effect even under a variety of true underlying data structures and which captures the 
variation inherent in the process of estimating the propensity scores by employing a subset 
of the available measured covariates. 
The hierarchical model described above is by no means the only approach at a 
Bayesian strategy for directly sampling the causal estimand, but an additional advantage it 
carries is flexibility in allowing for the inclusion of constraints on the parameter space that 
be required to analyze real data sets arising from various applications. Such constraints 
may be incorporated by an appropriate prior specification, or modification of the particular 
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parameters affected. An example of this flexibility is provided in Section 3.4 in the analysis 
of the case study data. 
We would like to demonstrate that this is a viable construction for estimating 
average treatment effects in observational data. We follow typical Bayesian methods and 
compute the full joint posterior distribution, as well as the conditional posterior 
distributions for all of the parameters (see Appendix 3 for full details on the derivations of 
the posterior conditional distributions). We note that the parameters 𝜏, 𝜃, 𝜎 , 𝜈 , 𝑎𝑛𝑑 𝜷 all 
have conjugate constructions and hence have specifiable conditional posterior 
distributions. These five parameters may be sampled using a Gibbs sampling approach. 
The remaining three parameters, 𝒑, 𝜶, and 𝜆, have conditional posterior distributions that 
are unknown; for these, we will need to employ some Markov chain Monte Carlo (MCMC) 
approach for the posterior sampling (Gelman et al., 2013). 
 
3.3 Simulation 
Although we have a number of parameters for which we plan to take posterior 
samples, our focus is primarily on 𝜏, the average treatment effect. In order to test and 
demonstrate that the proposed model may be used to gain accurate information about 𝜏, we 




3.3.1 Simulation procedure 
To describe the simulation study, we use the ADEMP framework advised by Morris 
et al. (2019). ADEMP stands for Aims, Data generating mechanisms, Estimands, Methods, 
and Performance metrics. 
 
Aims: What specifically do we want to learn from the simulation study? 
This study is more to demonstrate proof-of-concept, rather than to delineate 
conditions under which the proposed method is superior to other methods (see Morris, p. 
2077). We wish to evaluate the Bayesian sampler created to implement the Bayesian causal 
inference method devised. In particular, we intend to evaluate the small-sample bias of the 
proposed method; evaluate the variance of the estimator; and evaluate the method’s 
robustness under varying magnitudes and sources of uncertainty in the data being studied. 
 
Data-generating mechanisms: How will simulated data sets be generated? 
We begin by generating a design matrix of dimension n x 5 (𝑛 ∈ {100, 500, 1000}), 
with one column for the intercept and 4 columns for mutually independent and normally 
distributed covariates. We use this design matrix to generate n observations of the binary 
treatment, 𝑇 ∈ {0,1}, 𝑖 = 1,2, … , 𝑛, each distributed as 𝐵𝑒𝑟𝑛𝑜𝑢𝑙𝑙𝑖(𝑝 ) where 𝑝 =
Pr(𝑇 = 1|𝑿 ). The 𝑝 s are obtained from the underlying model 𝑙𝑜𝑔𝑖𝑡[Pr(𝑇 = 1|𝑿)] =
𝑿𝜷 + 𝜖 . We use 𝜷 = {0, 4, −2, 0, 0}, and 𝜖 ~𝑁 0, 𝜎 . 𝜎  is a parameter varied in 
different simulation settings; we refer to this parameter as “treatment-level noise,” and it 
reflects the fact that the treatment probabilities are viewed as random variables, not fixed 
probabilities. Finally, having generated the design matrix 𝑿 and the treatment status 𝑇, we 
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generate an outcome value 𝑌~𝑁 𝜃 + 𝑇𝜏, 𝜎 . 𝜎  is another parameter varied in different 
simulation settings. It controls the random noise associated with the outcome. 
It is worth emphasizing that we are not generating the simulated data according to 
the Bayesian hierarchical structure described in Section 3.2. That structure is used to 
facilitate a Bayesian approach at estimating the treatment effect, but it would be far-fetched 
to imagine that any particular data set would have exactly that structure as its underlying 
data generating mechanism. Furthermore, we want an analysis method that is robust and 
broadly applicable, in other words, that is effective under a variety of underlying data 
generating mechanisms. Our construction of the simulated data sets provides us the 
flexibility of testing many different potential data generating mechanisms, all sharing a 
general structure. 
 
Estimands: What is the target of the study? 
The proposed method is intended to produce estimates for 𝜏, the ATE. 
Consequently, the simulation study targets that estimand. We compare to the 
nonparametric IPW estimate, ?̂? . . Note that the proposed method involves several 
additional parameters. These weakly identified parameters are not part of the target of the 
study. We monitor them to understand aspects of how the method is working, but we do 
not require them to converge to “actual” values. 
 
Methods: What methods are to be tested or compared? 
Here, “method” refers to an approach for estimating causal treatment effects, as 
understood within the causal inference framework. We are primarily comparing the 
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proposed method described in Section 3.2 with the nonparametric IPW method using 
stabilized weights (Lunceford & Davidian, 2004). 
Specific details about the implementation of the Bayesian method are partially 
general to the model, and partially specific to the simulation setup. For example, regardless 
of the simulation setup, certain parameters have specifiable posterior conditional 
distributions, and hence we use a Gibbs sampling approach for them. Other parameters 
have posterior conditional distributions of unknown form. For those, in this simulation, we 
use a Metropolis-Hastings approach with a random walk technique for drawing new values, 
i.e., we start with the previous value, add a small random perturbation to it, and then assess 
the acceptance probability of the new value. Other approaches could be used, such as 
drawing new values (rather than just incremental change magnitudes from existing value) 
from an actual known probability distribution. Details of the derivations of the conditional 
posterior distributions are provided in Appendix 3. 
 
Performance measures: By what criteria will the methods be measured and compared? 
Evaluation of the proposed method is conducted first by assessing convergence of 
the posterior samples for the measures of primary interest. For comparison of the proposed 
method against the IPW method, we use 𝐵𝑖𝑎𝑠(?̂? ), 𝑉𝑎𝑟(?̂? ), 𝑀𝑆𝐸(?̂? ); 
𝐵𝑖𝑎𝑠(?̂? ), 𝑉𝑎𝑟(?̂? ), 𝑀𝑆𝐸(?̂? ); and the coverage rates of the different estimators. 
Note that Bayesian sampling diagnostics, such as convergence and absence of 
autocorrelation, are not performance measures; rather, these are prerequisites for 
establishing that the proposed Bayesian approach behaves acceptably in producing output 




3.3.2 Simulation results 
The results from the simulation study are summarized in Figure 3.1 and Table 3.1. 
The simulation modified settings for outcome-level noise (“oln”), treatment-level noise 
(“lln”), and sample size (“n”). For each combination of settings, Figure 3.1 displays box 
plots of ATE estimates for 100 simulated data sets. For each simulated data set, ?̂? was 
computed by means of the Bayesian hierarchical approach described in the previous 
section, as well as via the IPW approach. Meanwhile, Table 3.1 summarizes the 200 
different estimates for each scenario in terms of average bias, 95% CI (credible interval for 
Bayesian method, bootstrap percentile confidence interval for frequentist method) 




Figure 3.1: Boxplots of simulation study estimates of 𝜏 in 18 scenarios. Comparison of Bayesian 
(BYSN) and Inverse Probability Weighting (IPW) methods for estimating ATE. Simulation 
scenarios vary by treatment-level noise (“lln,” columns), outcome-level noise (“oln,” top three rows 
vs. bottom three rows), and sample size (“n”). The tighter, more precise spread of estimates is 
apparent for the Bayesian method as opposed to IPW, and for the lower setting of outcome-level 
noise. Treatment-level noise does not noticeably affect the distributions of the estimates. 
 
Several patterns are evident in Figure 3.1. First, the MCMC posterior estimates for 
𝜏 have much smaller variations (much higher precision) than the corresponding IPW 
estimates. This is true for every combination of parameter settings. Second, looking across 
the three columns of the figure, changes in treatment-level noise do not have a noticeable 
impact on the spread of effect estimates, for either method. Third, in contrast to the previous 
point, an increase in outcome-level noise does have an impact on the spread of effect 
estimates, specifically by widening the distributions of estimates. This holds consistent for 
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all settings of treatment-level noise and sample size, as well as for both methods. Fourth, 
bias is low, indicating unbiasedness or near unbiasedness of the procedures. 
Table 3.1: Comparison of Bayesian and IPW simulation study results by 𝜎 , 𝑛, and 𝜎 . 
lln=0.0 lln=0.6 lln=2.2
BYSN IPW BYSN IPW BYSN IPW
oln=1.5 n=100 Bias -0.049 -0.214 -0.044 -0.236 -0.013 -0.123
CI cvrg rt. 0.940 0.920 0.950 0.910 0.940 0.910
Avg. CI width 1.132 2.876 1.130 2.881 1.124 2.511
n=500 Bias 0.015 -0.052 0.005 -0.119 0.016 -0.017
CI cvrg rt. 0.870 0.900 0.850 0.860 0.910 0.920
Avg. CI width 0.492 2.261 0.489 2.220 0.504 1.556
n=1000 Bias 0.002 0.036 0.011 0.061 -0.017 0.075
CI cvrg rt. 0.810 0.890 0.850 0.870 0.900 0.940
Avg. CI width 0.352 1.910 0.359 1.842 0.359 1.309
oln=3.0 n=100 Bias -0.127 -0.028 -0.086 -0.471 0.076 0.130
CI cvrg rt. 0.910 0.940 0.950 0.890 0.920 0.940
Avg. CI width 2.282 5.904 2.252 5.673 2.264 5.018
n=500 Bias -0.004 -0.073 0.023 -0.267 -0.001 -0.230
CI cvrg rt. 0.870 0.840 0.870 0.860 0.930 0.880
Avg. CI width 0.988 4.231 0.974 4.485 0.994 2.951
n=1000 Bias 0.005 -0.239 0.011 0.122 0.012 -0.027
CI cvrg rt. 0.880 0.910 0.850 0.910 0.900 0.900
Avg. CI width 0.731 3.943 0.714 3.678 0.755 2.608  
Notes: oln = outcome-level noise (𝜎 ); n = sample size; lln = treatment-level noise (𝜎 ). 
CI: for the Bayesian method, the 95% credible interval for the second 50% of 10,000 MCMC 
repetitions (the first 50% of posterior samples deleted for burn-in); for the IPW method, 95% 
confidence interval (table shows average coverages and widths of the empirical 95% bootstrap 
confidence intervals resulting from 100 bootstrap samples for each repetition within each 
simulation setting). 
 
The aim for this simulation study as described in the previous sub-section was to 
evaluate whether the proposed Bayesian hierarchical scheme is a viable approach for 
sampling and estimating the causal estimand. The results shown in Figure 3.1 and Table 
3.1 indicate that the method is indeed successfully estimating the average causal effect, and 




3.4 Case study 
To demonstrate how the proposed method may be put into practical use, we apply 
it to the Lindner dataset contained within the PSAgraphics R package (Helmreich & 
Pruzek, 2009): 
The lindner data contain data on 996 patients treated at the Lindner Center, Christ 
Hospital, Cincinnati in 1997. Patients received a Percutaneous Coronary 
Intervention (PCI). The data consists of 10 variables. Two are outcome: lifepres 
ranges over two values, 11.4 or 0 depending on whether patients survived to six 
months. Secondly, [cost] contains the costs in 1998 dollars for the first six 
months… after treatment with the drug abciximab…. The treatment variable is 
abcix, where 0 indicates standard PCI treatment and 1 indicates standard PCI 
treatment and additional treatment in some form with abciximab. Covariates 
include acutemi, 1 indicating a recent acute myocardial infarction and 0 not; 
ejecfrac for the left ventricle ejection fraction, a percentage from 0 to 90; ves1proc 
giving the number of vessels (0 to 5) involved in the initial PCI; stent with 1 
indicating coronary stent inserted, 0 not; diabetic where 1 indicates that the patient 
has been diagnosed with diabetes, 0 not; height in centimeters; and female coding 
the sex of the patient, 1 for female, 0 male. 
 
In this analysis, we focus on the cost outcome variable. The primary research 
question is whether there is a causal association between use of the drug abciximab and 6-
month hospital costs. Higher 6-month hospital costs for those using the drug may well be 
justified if the drug is effective at extending life spans. However, to understand the cost 
effectiveness of the drug, it is necessary to quantify the causal difference in hospital costs. 
As this is observational data, care must be taken to control for possible confounding 
variables, i.e., other variables that may affect both the outcome (6-month hospital costs) 
and the probability of treatment. To alleviate issues with skewness and extreme positive 
outliers, we work with the natural logarithm of cost. We also remove 26 observations for 
patients who died within 6 months of the procedure, so that we are comparing only patients 
with full 6-month costs. 
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Table 3.2 presents the baseline distributions of all covariates, stratified by the 
treatment. The table also shows the absolute standardized mean difference (ASMD) for 
each covariate, both before and after adjustment based on the estimated propensity scores. 
The ASMD is a metric commonly used in propensity score analysis for evaluating covariate 
balance before and after adjustment on the propensity scores (Austin & Stuart, 2015). The 
propensity score serves two roles; it is, by definition, the probability of the subject being 
in the treatment group, conditional on that subject’s covariates. It is also a balancing score, 
by which is meant that conditional on the propensity score, the distribution of covariates is 
balanced between the treatment and control groups (Rosenbaum & Rubin, 1983). It is this 
latter role, the balancing role, that is most important for controlling for confounding bias 
in observational studies (Shortreed & Ertefaie, 2017). The table demonstrates that the 
baseline propensity score successfully balances all covariates; the maximum adjusted 
ASMD is 0.102, which is sufficiently low. 
Table 3.2: Baseline characteristics stratified by treatment group, 
and covariate balance, Lindner dataset 
 
* Treatment is use of the drug abciximab. 
ASMD: absolute standardized mean difference; MI: myocardial infarction 
 
Stratified by Treatment* Covariate Balance
Control Treatment Unadjusted Adjusted
283 687 ASMD ASMD
Mean (sd) Mean (sd)
Cost (1998 $s) 14,253 (14,488) 16,008 (8,910)
ln(Cost)     9.38 (0.53)     9.58 (0.42)
Mean (sd) Mean (sd)
Height (cm)   171.63 (10.50)   171.50 (10.68) 0.012 0.035
Ejection fraction (%)    52.93 (9.62)    50.46 (10.38) 0.247 0.046
# Vessels in procedure     1.20 (0.47)     1.46 (0.70) 0.433 0.014
# (%) # (%)
Stent used (yes)      165 (58.3)      484 (70.5) 0.256 0.102
Gender (female)      109 (38.5)      226 (32.9) 0.117 0.097
Diabetic (yes)       73 (25.8)      139 (20.2) 0.132 0.024
Acute MI within 1 wk (yes)       16 ( 5.7)      121 (17.6) 0.380 0.090








In the Bayesian approach, after initial estimation via logistic regression of the 
treatment on the covariates, the vector of treatment probabilities changes with each MCMC 
step. Consequently, the balance of the covariates between the treatment and control groups 
changes. Because the central role of the propensity score is to balance the covariates, we 
impose a constraint to ensure that adequate covariate balance is maintained as we progress 
through the Markov chain posterior sampling. As mentioned in Section 3.2, the proposed 
method is flexible in allowing constraints to be incorporated into the prior specification. 
Here, we impose the constraint by requiring that 𝑀𝑎𝑥(𝐴𝑆𝑀𝐷) < 0.2. If the new sample 
of the vector of propensity scores results in any covariate having ASMD > 0.2, then we 
reject that sample. As the ASMD metric is a function of the 𝑝 s (that is, a function of the 
subject-level Bernoulli treatment group probabilities), this constraint is imposed on the 
prior distribution of the 𝑝 s. Whereas in the statement of the model in Section 3.2, we had: 
𝑝 |𝛼 , 𝜆~𝐵𝑒𝑡𝑎(𝜆𝛼 , 𝜆) 
we now modify this prior to incorporate the constraint needed for this case study, as: 
𝒑|𝜶, 𝜆~ 𝐵𝑒𝑡𝑎(𝜆𝛼 , 𝜆) ⋅ 𝐼{𝑀𝑎𝑥(𝐴𝑆𝑀𝐷) < 0.2} 
As shown above in Table 3.2, of the 970 patients who survived to six months, 687 
(70.8%) received the treatment drug, and the remaining received only standard care. The 
average 6-month costs for the treatment group was $16,008, while for the control group it 
was $14,253. This leads to a naïve (unadjusted) estimate for the cost difference of $1755, 
with a 95% confidence interval of (-$62, $3572). We used the proposed method to estimate 
the average treatment effect of the use of the drug abciximab on 6-month hospital costs. 
We ran 10,000 Bayesian MCMC iterations, dropping the first 50% for burn-in. The MCMC 
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chains showed good convergence even before the 5000th iteration. From this method, we 
estimated a covariate-adjusted treatment effect (cost difference) of $2078, with a 95% 
credible interval of ($1287, $2860). This point estimate is nearly 20% higher than the 
unadjusted/naïve estimate of $1755, and the credible interval is only 43% as wide as the 
unadjusted confidence interval. 
For further comparison, we also used the frequentist IPW propensity score method 
(using stabilized weights), with 200 bootstrap samples to estimate the standard error of the 
estimated treatment effect. The point estimate from this approach was $1970, with a 95% 
empirical bootstrap confidence interval of ($911, $2916). Figure 3.2, below, illustrates the 
distributions of the Bayesian posterior estimates and of the IPW bootstrap estimates, as 
well as the point estimate and confidence interval of the unadjusted approach. We observe 
that the unadjusted estimate is simply inappropriate in this case: basic assumptions of 
normally distributed data and independent observations that are involved in estimating the 
difference in means of two populations are clearly violated. The IPW point estimate is 
similar to that of the Bayesian method, but the confidence interval is about 30% wider. We 
believe that the Bayesian credible interval represents a reliable estimate of the true causal 




Figure 3.2: Densities of posterior and bootstrap samples, case study. For Bayesian (BYSN) 
method, density of 5000 posterior values (10K posterior samples, 50% removed for burn-
in). For Inverse Probability Weighting (IPW), density of 200 bootstrap samples. Vertical 
reference lines indicate boundaries for the 95% credible interval (BYSN) and 95% 
empirical bootstrap confidence interval (IPW). Naïve/unadjusted point estimate and 95% 
confidence interval also depicted. 
 
3.5 Discussion and conclusions 
There are many statistical considerations involved in the analysis of observational 
data for causal inference. Likewise, there are many potential approaches one may consider 
in such scenarios. On the frequentist side, a variety of propensity score (and other) methods 
have been developed over the past several decades. On the Bayesian side, typically 
Bayesian methods are used for estimating posterior predictive distributions for “missing” 
counterfactual outcomes or for testing sensitivity to various assumptions. In the approach 
described in this paper, we attempt to focus directly on the core research question, 
specifically, what is the average treatment effect of the treatment on the outcome? 
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The simulation study described above provides a proof-of-concept for the proposed 
Bayesian approach. It demonstrates that the approach can work, and that it compares 
favorably against the frequentist IPW method. Further enhancements to the simulation 
study could test a variety of underlying data structures, as well as scenarios with binary 
outcomes, or multilevel treatments. As is common in Bayesian analysis, computational 
time is a consideration. With small to moderate sized datasets, this method performs quite 
well. With large datasets (say n > 10,000 and/or p > 50), the computational demands from 
this method may become onerous. 
In this project, we wish to estimate the average causal effect, but we approach the 
problem from a Bayesian perspective. We use a Bayesian hierarchical structure to 
conceptualize the data, and then attempt to use posterior sampling to estimate the causal 
effect parameter directly. The hierarchical model described above is by no means the only 
way to formulate the problem. In Appendix 4, we provide an alternative formulation and 
apply a weighted likelihood approach for summarizing the data, which will be investigated 







INNOVATIVE APPROACH FOR SUBGROUP ANALYSIS 
 
4.1 Introduction 
Observational studies differ from experimental studies in that assignment of 
subjects to treatments is not randomized but rather occurs due to natural mechanisms, 
which are usually hidden from the researchers. Yet objectives of the two studies are 
frequently the same: identify the treatment effect of some exposure on a population. 
Furthermore, in both types of studies it is frequently of interest to learn whether treatment 
effects differ across particular subgroups of subjects, a situation sometimes termed 
treatment heterogeneity. While these objectives can be achieved directly in an experimental 
context due to the design imposed on the study, in an observational study special care must 
be taken to avoid confounding bias in treatment effect estimates, particularly when the 
number of covariates is large. This research focuses on avoiding confounding bias in 
estimation of treatment effect, with special focus on identifying effect modifiers. We 
present a method which efficiently selects effect modifiers from the set of covariates and 
computes unbiased estimates for subgroups of interest. The goal is to deliver more targeted 
advice describing circumstances where a treatment may be more beneficial for one or some 
groups versus others. 
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There are several motivations for being concerned with subgroup analysis 
(Lipkovich, Dmitrienko, & B D'Agostino Sr, 2017). First, in the context of a Phase III 
clinical trial, it may be that the trial fails overall, but the experimental treatment may still 
offer benefit to some subset(s) of the population. Or, perhaps the Phase III trial is 
successful, but the sponsor wants to target the experimental treatment to the subset of the 
population likely to benefit the most. Similarly, but on the negative side, it may be that due 
to differing safety profiles across the population, regulators deem certain labeling 
restrictions are needed for a drug on the market. Finally, with ever-increasing attention 
being given to “personalized medicine,” the goal of identifying optimal treatment regimes 
from a variety of available treatments often leads to methods involving subgroup analysis 
(Foster, Taylor, Kaciroti, & Nan, 2015). Any of these motivations, or variations of them, 
could occur in situations in which observational data, rather than experimental data, is the 
only – or the most feasible – data available for informing the research question. 
A helpful framework for classifying statistical methods related to subgroup analysis 
is provided by Lipkovich et al. (2017). The authors distinguish four types of methods that 
fall along a spectrum from purely confirmatory to focused on subgroup discovery. First is 
confirmatory subgroup analysis, which is concerned with evaluating a small number of 
pre-defined subgroups. Second is exploratory subgroup evaluation, in which analysis 
focuses on a relatively small number of subgroups that are pre-specified, and where the 
focus is mostly on interactions between treatments and covariates, as well as evaluating 
consistency. Third is post-hoc subgroup evaluation, in which post-hoc assessments are 
made of the differing treatment effects within a relatively small number of subgroups. This 
group is more ad hoc than the previous group and would apply to situations dealing with 
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regulatory inquiries, post-marketing activities, and safety monitoring. Fourth is subgroup 
discovery, in which the goal is selecting the most promising subgroups out of a potentially 
large number of candidates. Data mining or machine learning algorithms are likely to be 
employed here, and the objective is frequently to define subgroups for future analysis in 
confirmatory studies, such as done by Wang, Schoenfeld, Hoeppner, and Evins (2015). 
One extremely common theme in the subgroup analysis literature is that of 
multiplicity control, i.e., controlling Type I error rate. Lipkovich et al. (2017) reviewed a 
large amount of literature that provided guidelines that should be followed in conducting 
subgroup analysis. The authors summarized the “general theme” of the guidelines in six 
ideas; five of these, arguably, relate to multiple comparison issues. In arguing for 
“principled data-driven strategies” for conducting subgroup analysis, as opposed to the 
“guideline-driven approach,” the authors expand on the idea of necessary multiplicity 
control in an interesting way; for confirmatory subgroup analysis, multiplicity control must 
be used but must encompass the entire subgroup identification strategy. Furthermore, the 
multiplicity control should be used in conjunction with “complexity control.” While the 
former is concerned with controlling Type I error rates, either via strong family-wise error 
rate control or via limited false discovery rate, the latter is concerned with avoiding data 
overfitting. As the authors put it, “[a]pplying multiplicity adjustments following subgroup 
selection is an important but insufficient step, as it would not help find the right covariates 
‘after the fact’” (p. 139). The complexity control should be built into the full process of 
model selection, e.g., via penalized likelihood methods; this lessens the multiplicity 
burden, making these two ideas complementary concepts that “should be used in 
combination” (p. 139). 
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Another common theme in the subgroup analysis literature is the distinction 
between “black box” methods and those with readily interpretable decision rules. Laber 
and Zhao (2015) explain that methods based on decision trees (Breiman, 2001) are popular 
because they fit this latter description, and as such, they are easily implemented in the field. 
In contrast, regression-based approaches (e.g., Qian and Murphy (2011) and Brinkley, 
Tsiatis, and Anstrom (2010)) typically face the choice between constructing parsimonious 
models leading to more interpretable decision rules but subject to model misspecification, 
or more complex models that may avoid misspecification but result in “unintelligible” 
treatment rules. Tian, Alizadeh, Gentles, and Tibshirani (2014) propose such a regression-
based model; in their approach, they use modified covariates in a regression of the outcome 
on treatment and treatment-covariate interaction terms and stratify subjects based upon 
their resulting predicted treatment response profile; while this approach serves to divide up 
an existing data set into, say, a low score and a high score group (with one or the other of 
those indicated as benefiting more from the treatment), no particular rules are provided for 
guiding decisions about future subjects. 
In this project, we propose a flexible outcome model, where the control group 
response profile is captured by a non-parametric function, and treatment heterogeneity is 
captured by the interaction term between treatment and a linear combination of covariates. 
Penalized regression and inverse probability weighting (IPW) are applied to select the 
important variables in the interaction, thus the effect modifiers and subgroups  can be 
identified. The approach is quite flexible, and it can be applied to data from either 
randomized trials or observational studies. 
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The structure of the remainder of this chapter is as follows: in Section 4.2, we 
describe the context and a proposed method for conducting subgroup analysis. This method 
fits within the fourth category of subgroup analysis described above; it is concerned with 
identifying the right treatment for a given patient, rather than identifying the right patient 
for a given treatment. In Section 4.3, we describe the simulation study we executed to test 
the proposed methodology. In Section 4.4, we illustrate application of the method to a case 




Let (𝑿, 𝑇, 𝑌) indicate the triplet for the baseline covariates, treatment group and 
outcome variable, with 𝑇 ∈ {0,1}. Let (𝑿 , 𝑇 , 𝑌 ) (𝑖 = 1, … , 𝑛) indicate a random sample 
from a population of interest. The sample could result from either a randomized 
experimental design or an observational study. The following model (1) has often been 
used (Fu, Zhou, & Faries, 2016) to examine treatment heterogeneity, identify the subgroup 
which may benefit from the treatment, and select the optimal treatment regime:  
𝐸(𝑌|𝑿, 𝑇) = ℎ(𝑿) + 𝑔(𝑿)𝑇.                                        (1) 
In particular, the interaction term 𝑔(𝑿)𝑇 plays an important role in identifying the 
optimal treatment or identifying the subgroup which receives more benefit from the 
treatment. We use the concept of potential outcomes (Rubin, 1974) to look at the role of 
𝑔(𝑿). We denote with 𝑌( ) and 𝑌( ), respectively, the potential outcomes for control and 
treatment for a given subject with covariates 𝑿. Here we assume that exchangeability and 
consistency hold (Hernán & Robins, 2020):  (i)  exchangeability means that  𝑌( )⟂T|𝐗, 
and (ii) consistency means that the observed outcome equals the potential outcome 
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corresponding to the treatment the subject receives, that is, 𝑌 = 𝑇𝑌( ) + (1 − 𝑇)𝑌( ). If 
we assume model (1) is correctly specified, then the treatment effect for a subject with 
covariate 𝑿 would be  
𝐸 𝑌( ) − 𝑌( )|𝑿 = 𝐸 𝑌( )|𝑿 − 𝐸 𝑌( )|𝑿  
= 𝐸 𝑌( )|𝑿, 𝑇 = 1 − 𝐸 𝑌( )|𝑿, 𝑇 = 0       (by exchangeability) 
= 𝐸[𝑌|𝑿, 𝑇 = 1] − 𝐸[𝑌|𝑿, 𝑇 = 0]              (by consistency) 
= [ℎ(𝑿) + 𝑔(𝑿)] − [ℎ(𝑿)]                         (by (1)) 
= 𝑔(𝑿). 
We want to identify the group in which subjects have a beneficial treatment effect, 
that is 𝒮 = {𝐗: E Y( ) − Y( )|𝐗 > 0}. In other words, 𝒮 = {𝑿: 𝑔(𝑿) > 0}. Here, the 
primary interest is to estimate the contrast 𝑔(𝑿) to identify the subgroup which benefits 
more from treatment. To facilitate a clinical decision, we would like the 𝑔(𝑿)  function to 
be simple and to capture the main variables for decision making. The ℎ(𝑿) function 
captures the response profile under control, which is not of direct interest when the research 
question is to examine whether any subgroup has a differing response to treatment. Thus, 
we can consider ℎ(𝑿) to be a nuisance function, which is used to facilitate accurate 
estimation of the 𝑔(𝑿) function. The structural nested mean model (SNMM) (Hernán & 
Robins, 2020) uses a parametric function for 𝑔(𝑿) (for example, 𝑔(𝑿;  𝜷) = 𝑿𝜷) to 
estimate the parameter 𝜷. The first step is to link the SNMM with the observed data; using 
the assumption of consistency, we have (Hernán & Robins, 2020): 
𝑌( ) = 𝑌 − 𝑇𝑔(𝑿;  𝜷).                                               (2) 
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When only one parameter 𝛽 is involved, 𝛽 has been estimated by minimizing the 
association between 𝑌( ) and 𝑇. Specifically, 𝛽 is obtained by solving the following 
estimating equations: 
∑ 𝑌 − 𝑇 𝑔(𝑋 ;  𝛽) (𝑇 − 𝐸(𝑇 |𝑋)) = 0.                                  (3) 
Here, 𝐸(𝑇|𝑋) = Pr(𝑇 = 1|𝑋), the probability, conditional on covariates, of being in the 
treatment group. In a randomized experiment, this probability is a constant, while in an 
observational study, it is the propensity score and must be estimated. 
When 𝜷 is a vector, in what is termed the A-learning method (Schulte, Tsiatis, 
Laber, & Davidian, 2014) the following estimating equations have been proposed 
(Vansteelandt & Joffe, 2014): 
∑
( ; )
{𝑌 − 𝐸(𝑌 |𝑋 ) − 𝑔(𝑋 ; 𝛽)(𝑇 − 𝐸(𝑇 |𝑋))}{𝑇 − 𝐸(𝑇 |𝑋)} = 0.         (4) 
Note that 𝐸(𝑌|𝑋) ≠ ℎ(𝑋), instead  
𝐸(𝑌|𝑋) = 𝑦𝑓(𝑦|𝑥)𝑑𝑦 = 𝑦𝑓(𝑦, 𝑡|𝑥)𝑑𝑡𝑑𝑦 = 𝑦𝑓(𝑦|𝑥, 𝑡)𝑓(𝑡|𝑥)𝑑𝑡𝑑𝑦 
= 𝑦𝑓(𝑦|𝑥, 𝑡 = 0)𝑓(𝑡 = 0|𝑥)𝑑𝑦 + 𝑦𝑓(𝑦|𝑥, 𝑡 = 1)𝑓(𝑡 = 1|𝑥)𝑑𝑦 
= 𝑦( )𝑓 𝑦( ) 𝑥, 𝑡 = 0 𝑓(𝑡 = 0|𝑥)𝑑𝑦( )
+ 𝑦( )𝑓 𝑦( ) 𝑥, 𝑡 = 1 𝑓(𝑡 = 1|𝑥)𝑑𝑦( ) 
= 𝐸 𝑌( ) 𝑋 𝑃𝑟(𝑇 = 0|𝑋) + 𝐸 𝑌( ) 𝑋 𝑃𝑟(𝑇 = 1|𝑋) 
= ℎ(𝑋) 1 − 𝐸(𝑇|𝑋) + ℎ(𝑋) + 𝑔(𝑋) 𝐸(𝑇|𝑋) 




We define ℎ (𝑿) = 𝐸(𝑌|𝑿) = ℎ(𝑿) + 𝑔(𝑿)𝐸(𝑇|𝑿). It has been shown (Schulte 
et al., 2014) that Equation (4) provides consistent estimates for the contrast function if the 
model for 𝑔(𝑿) and the propensity score model are correctly specified. Also, Lu, Zhang, 
and Zeng (2013) assume ℎ(𝑋) to be a parametric function, for example ℎ(𝑋;  𝛾) = 𝑋𝛾. 
However, our objective is not to estimate ℎ(𝑋), nor to estimate ℎ (𝑋). Instead, we are 
interested in estimating the interaction funtion 𝑔(𝑋), which captures the treatment 
heterogeneity. Let us assume that 𝑔(𝑋) has a functional form as 𝑔(𝑋 ; 𝛽). The loss function 
(i.e., the sum of squares for errors) 𝐿 (𝛽) = ∑ [𝑌 − ℎ(𝑋 ) − 𝑇 𝑔(𝑋 ;  𝛽)]  can be 




[𝑌 − ℎ (𝑋 ) − 𝑔(𝑋 ;  𝛽)(𝑇 − 𝐸(𝑇 |𝑋 ))] .                        (5) 
Estimating equation (4) can be linked with the loss function in equation (5) (Lu et al., 
2013). The parameter 𝛽 can be estimated by  
𝜕𝑔(𝑋 ; 𝛽)
𝜕𝛽
{𝑌 − ℎ(𝑋 ; 𝛾) − 𝑇 𝑔(𝑋 ; 𝛽)}{𝑇 − 𝐸(𝑇 |𝑋)} = 0.            (6) 
The derivative of 𝐿 (𝛽) with respect to 𝛽 will not result in equation (6), which is the 
equation related to A-learning. Thus, we use the objective function in equation (5). We 
propose using a more flexible and nonparametric model for ℎ (𝑋) (for example, the 
generalized boosted model (McCaffrey, Ridgeway, & Morral, 2004), or the random forest 
method (Breiman, 2001)), while we use a relatively simple model for 𝑔(𝑋;  𝛽). For 
example, we take 
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𝑔(𝑋 ;  𝛽) = 𝛽 + 𝑋 𝛽 + 𝑋 𝑋 𝛽 = 𝑋 𝛽, 
in other words, a simple linear combination of the variables we are interested in. 
We incorporate complexity control into the process by using lasso (Tibshirani, 1996) 
or the elastic net (Zou & Hastie, 2005) method to select the few important variables to 
identify the subgroup that receives more benefit from the treatment. We propose to estimate 
ℎ(𝑿) non-parametrically and estimate 𝑔(𝑿;  𝛽) using penalized regression, as detailed in 
the following steps: 
(i) Obtain 𝐸(𝑇|𝑋) = 𝑃𝑟 (𝑇 = 1|𝑋): For an observational study, we estimate the 
probability, perhaps via logistic regression; for a randomized study, 𝐸(𝑇|𝑋) is 
assumed to be a known constant. For example, 𝐸(𝑇|𝑋) might equal 0.5 for a 
randomized trial with equal probability of control or treatment assignment. 
(ii) Estimate 𝐸(𝑌|𝑋) = ℎ (𝑋) nonparametrically: We fit the model 𝐸(𝑌|𝑋) =
ℎ (𝑋) using a nonparametric approach (e.g., random forest or generalized 
boosted model) to obtain an estimate of  ℎ (𝑋), which we denote as ℎ (𝑋). For 
this step, we ignore the treatment variable and fit the outcome model using all 
observed data, including observations from both control and treatment subjects.  
(iii) Estimate the contrast function 𝑔(𝑋; 𝛽): We set 𝑌∗ = 𝑌 − ℎ (𝑋), and set 𝑋∗ =
𝐷𝑖𝑎𝑔(𝑇 −  𝐸(𝑇|𝑋))𝑋 . We then use lasso or the elastic net method to 
estimate 𝑔(𝑋;  𝛽) by minimizing 𝐿(𝛽) = (𝑌∗ − 𝑋∗𝛽) (𝑌∗ − 𝑋∗𝛽). The 
minimization of the loss function in this step using penalized regression 
methods results in the selection of variables that interact with the treatment to 
modify the treatment effect. 
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(iv) Identify subgroup(s) benefiting from treatment: We define the estimated 
subgroup as 𝒮 = {X: 𝑔 𝑋; 𝛽 > 0}, or, depending on the specific application, 
we may use 𝒮 = {𝑋: 𝑔 𝑋; 𝛽 > 𝛿} for some clinically meaningful value 𝛿. 
 
4.3 Simulation 
4.3.1 Simulation procedure 
As a proof-of-concept we designed a simulation study to implement the proposed 
method. In this section we use the ADEMP framework described by Morris et al. (2019) 
as a methodical approach for planning and describing our simulation study. Our decisions 
for the various aspects of the study were to a large extent influenced by the simulation 
study conducted by Lu et al. (2013), which is for randomized controlled trials (RCTs). Our 
approach is applicable to both RCTs and observational studies. 
 
Aims: What specifically do we want to learn from the simulation study? 
Our aims for the simulation study were to demonstrate that our proposed method is 
effective at identifying subgroups under a variety of underlying data conditions. The 
outcome was designed such that a higher value indicated a more desirable response.  
 
Data-generating mechanisms: How will simulated data sets be generated? 
Our data generating mechanism varied those dimensions that were of greatest 
importance in determining the conditions under which the proposed method is effective. 
As in Lu et al. (2013), we used 10 covariates, but whereas those authors solely used a 
correlated structure, we compared performance under both correlated and independent 
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covariates. We do advise our method for both experimental and observational data, and so 
while Lu et al. (2013) treated only experimental data, we also included several different 
types of observational data scenarios, varying in the degree and type of confounding that 
was present. Other simulation parameters that were varied included sample size, underlying 
probability of treatment, signal-to-noise ratio, and treatment effect size. 
To describe our data generating mechanism in detail, we use the outcome model 
𝑌 = ℎ(𝑿; 𝜸) + 𝑇𝑔(𝑿; 𝜷) + 𝜖, while the probability of treatment is computed via the model 
𝑙𝑜𝑔𝑖𝑡(Pr[𝑇 = 1|𝑿]) = 𝑘(𝑿; 𝝓), where 𝑘(𝑿; 𝝓) = 𝝓 𝑿. We thus have three functions,  
ℎ(⋅), 𝑔(⋅), and 𝑘(⋅), that govern the relationships among covariates, treatment, and 
outcome. The h-function controls the complexity and linearity of the relationship between 
the outcome Y and the covariates, under no treatment. The g-function controls the nature 
of the interaction effects between the treatment and covariates; as described in Section 4.2, 
this is the key function for identifying subgroups. Finally, the k-function specifies the 
relationship between the covariates and the treatment.  
The simulation evaluated the proposed method under scenarios that differed first 
with respect to the complexity of the response profile under control (i.e., the h-function), 
and second with respect to the nature and degree of confounding (i.e., the k-function). Table 




Table 4.1: Settings for h-, g-, and k-functions in simulation scenarios. 
𝑌 = ℎ(𝑿; 𝜸) + 𝑇𝑔(𝑿; 𝜷) + 𝜖 
𝑋 = (𝑋 , 𝑋 , … , 𝑋 )~𝑀𝑉𝑁(0, 𝚺), 𝜖~𝑁(0, 0.5 ) 
𝑔(𝑿; 𝜷) = 𝜷 𝑿, where 𝑿 ≡ (1, 𝑿 )  
𝜷 = (1, 1, 𝟎 , −0.9, 0.8)  
𝟎  indicates a vector of zeroes of length 𝑑. 
Models for ℎ(𝑿; 𝜸):   Y1:   ℎ(𝑿; 𝜸) = 1 + 𝜸 𝑿 
  Y2:  ℎ(𝑿; 𝜸) = 1 + 0.5(𝜸 𝑿)(𝜸 𝑿) 
  Y3:  ℎ(𝑿; 𝜸) = 1 + 0.5 sin(𝜋𝜸 𝑿) + 0.25(1 + 𝜸 𝑿)  
           𝜸 = (1, −1, 𝟎 )  and 𝜸 = (1, 𝟎 , −1, 𝟎 , 1)  
Propensity score models: 
 
𝑙𝑜𝑔𝑖𝑡(Pr[𝑇 = 1|𝑿]) =
𝑘(𝑿; 𝝓) = 𝝓 𝑿. 
 𝝓 = (1, 𝟎 , 1, 1, 𝟎 ) ;  
𝝓 = (1, 𝟎 , 1, 1, 1, 0)  
𝝓 = (1, 𝟎 , 1, 0, 1, 1, 1, 1, 𝟎 )  
𝝓 = (1, 0, 1, 0, 1, 𝟎 )  
 𝝓 = 𝟎 , 𝑘(𝑿; 𝝓𝑹) = 0  (Randomized experiments) 
 
 In every case, 𝑔(𝑿; 𝜷) = 𝜷 𝑿, where 𝑿 ≡ (1, 𝑿 )  and 𝜷 = (1, 1, 𝟎 , −0.9, 0.8) ; 𝟎  
indicates the zero vector of length d. The three different formulations for the outcome, 𝑌, 
were obtained by varying the h-function. For Y1, ℎ(𝑿; 𝜸) = 1 + 𝜸 𝑿, an ordinary linear 
combination of the covariates; for Y2, ℎ(𝑿; 𝜸) = 1 + 0.5(𝜸 𝑿)(𝜸 𝑿); and for Y3, 
ℎ(𝑿; 𝜸) = 1 + 0.5 sin(𝜋𝜸 𝑿) + 0.25(1 + 𝜸 𝑿) , where 𝜸 = (1, −1, 𝟎 )  and 𝜸 =
(1, 𝟎 , −1, 𝟎 , 1) . These specifications were motivated by the intention of mimicing the 
simulation approach used in Lu (2013). However, whereas that study considered only 
experimental data, we also considered observational data where Pr(𝑇 = 1|𝑿) was assumed 
unknown. We experimented with four different approaches at constructing the Pr(𝑇 =
1|𝑿). In each case, the relationship could be expressed generally as 𝑙𝑜𝑔𝑖𝑡(Pr[𝑇 = 1|𝑿]) =
𝑘(𝑿; 𝝓) = 𝝓 𝑿. For specifications A, B, C, and D, we used 𝝓 = (1, 𝟎 , 1, 1, 𝟎 ) ; 𝝓 =
(1, 𝟎 , 1, 1, 1, 0) ; 𝝓 = (1, 𝟎 , 1, 0, 1, 1, 1, 1, 𝟎 ) ; and 𝝓 = (1, 0, 1, 0, 1, 𝟎 ) , 
respectively. These choices were made based upon considerations of how the covariates 
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were used in the h- and g-functions and the structure of confounding that resulted; the 
variance-covariance matrix for the correlated covariates scenarios, detailed in the next 
paragraph, also factored into making these decisions. The causal diagrams in Figure 4.1 
illustrate these relationships as resulting from the first h-function specification (Y1) and 
four different propensity score models. 
 
Figure 4.1: Structure of confounding in various simulation scenarios. These causal 
diagrams show the structure of confounding for the four observational data scenarios for 
the first specification of the outcome, Y. Small circles with numbers represent individual 
covariates, of which there are 10. The h-function and the g-function remain the same for 
these four scenarios; only the k-function, which specifies the relationship between the 
covariates and the probability of treatment, changes. 
 
Consequently, in our simulation, for each of the three constructions of Y, we tested 
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just described, in which during the estimation process we treated the propensity score as 
unknown, and the one experimental data scenario in which the propensity score was 
known. This gave 15 versions of the generated outcome values. The process for generating 
the data was as follows: we first generated values for 10 covariates and one error term, with 
sample size n. The covariates had a multivariate normal distribution, 
𝑿~𝑀𝑢𝑙𝑡𝑖𝑣𝑎𝑟𝑖𝑎𝑡𝑒 𝑁𝑜𝑟𝑚𝑎𝑙(0, 𝚺), and the error term had the distribution 𝜖~𝑁(0, 0.5 ). 
For the independent covariates scenarios, 𝚺 = 𝑰 , while for the correlated covariates 
scenarios, we used 𝐶𝑜𝑟𝑟 𝑋 , 𝑋 = 0.5| |, in keeping with Lu 2013.(Lu et al., 2013) We 
then used the values of the covariates 𝑿 to compute Pr(𝑇 = 1|𝑿) for the observational data 
scenarios, or we set Pr(𝑇 = 1|𝑿) = 0.5 for the experimental data scenarios. We then 
generated the vector of binary treatment indicators according to 
𝑇 ~𝐵𝑒𝑟𝑛𝑜𝑢𝑙𝑙𝑖(Pr(𝑇 = 1|𝑿 )). Finally, we computed Y using the known values of 𝑿 and 
𝑇 and the appropriate h- and g-functions for each specific scenario. 
 
Estimands: What is the target of the study? 
The target of this simulation study was accurate prediction. Hence we focused on 
the more general term “target” rather than “estimand” as described in Morris et al. (2019), 
Section 3.3.  
 
Methods: What methods are to be tested or compared? 
The proposed method, which is the subject of this paper, was the primary method 




Performance measures: By what criteria will the various methods be measured and 
compared? 
Following Lu et al. (2013), we employed several different performance measures. 
The most important of these was termed Percent Correct Decision (PCD). This could be 
expressed simply as 𝑃𝐶𝐷 = ∑ 𝐼 𝑠𝑖𝑔𝑛 𝑔 𝑋 ; 𝛽 = 𝑠𝑖𝑔𝑛 𝑔(𝑋 ; 𝛽) . We 
constructed 𝑌 such that larger values were more desirable; thus, 𝑔 𝑋 ; 𝛽 > 0 implied that 
subject i should be prescribed the treatment, while 𝑔 𝑋 ; 𝛽 < 0 implied that subject i 
should not be prescribed the treatment. PCD, then, measured how well the predicted 
decision matched the known best decision. Other performance measures (see Table 4.2) 
included mean squared error (MSE), measuring the accuracy of coefficient estimates in the 
g-function; the number of correctly dropped covariates (Corr0); the number of incorrectly 
dropped covariates (Incorr0); and the average proportion of times that the method selected 
the exactly correct set of covariates (Exact). 
 
4.3.2 Simulation results 
The simulation scenarios varied in terms of sample size, independence versus 
correlation of covariates, structure of confounding, and nature of the h-function. Table 4.2 
presents results for the largest sample size (n=1000); similarly structured tables of results 
for other sample sizes (n=400, 200 and 100) are presented in Appendix 5. 
From Table 4.2 we observe that the absolute levels of the PCD are typically in the 
high 90 percents for independent covariates, and in the mid-90 percents for correlated 
covariates, demonstrating that the proposed method leads, a great majority of the time, to 
the correct decision regarding whether a particular subject should receive treatment or not. 
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It is also apparent that the method performs better for independent than for 
correlated covariates; the ratio of the PCD of the correlated covariates scenarios to that of 
the independent covariates scenarios is always in the range of 0.95-0.99, i.e., the PCD is 
about 1% to 5% lower when covariates are correlated. Moreover, the number of correctly 
dropped covariates is close to seven, the true number in all scenarios, but the independent 
covariates scenarios performed slightly better than the scenarios with correlated covariates. 
Correlation engrained in the covariate structure will make it more difficult to accurately 
de-select those which are not involved in the g-function (see the ratio for the Corr0 metric 
in Table 4.2). 
Comparing the outcome models Y1, Y2, and Y3, the method does best for the least 
complicated h-function (Y1), then next best for the Y3 h-function, and third best for the 
Y2 h-function. Performance does not vary markedly under different approaches at 
specifying the covariate-treatment relationship in the observational data scenarios 
(specifications A, B, C, and D). For those scenarios, elastic net typically achieves a 
fractionally higher PCD than lasso, but a fractionally lower Corr0 and Exact; this can 
probably be explained by the fact that lasso is shrinking the estimated regression 
parameters more aggressively than is elastic net. These differences seem insubstantial, 
suggesting that either of these penalized regression approaches should achieve satisfactory 
results in the observational data scenarios. 
The number of incorrectly dropped covariates is 0 in almost all scenarios (Incorr0 
in Table 4.2), indicating that our proposed method selects the important variables very well. 
Although, the proposed method performs slightly better for experimental data (the last two 
rows of each of the three main vertical table sections) as compared to observational data 
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(rows 1 through 8 of each of the three main vertical table sections), the proposed method 
performs well for both experimental data and observational data. 
Table 4.2: Simulation results from 1000 Monte Carlo repetitions for each of the 15 
scenarios (3 outcome models × 5 PS models) under independent covariates and 
correlated covariates (N=1000) 
 
Notes: PCD=Percent Correct Decision; MSE=Mean Squared Error; Corr0=avg. # of 
covariates correctly estimated as 0 (in g-function); Incorr0=avg. # of covariates 
incorrectly estimated as 0 (in g-function); Exact=proportion of times the exactly correct 
set of covariates is selected 
Y1/Y2/Y3=different specifications of h-function; A/B/C/D=different specifications of k-
function; EN=elastic net; L=lasso 
 
4.4 Case study 
4.4.1 Case study background 
To demonstrate our proposed method, we applied it to a case study data set to 
identify the subgroup of patients with heavy alcohol use who may benefit from varenicline 
treatment (Litten et al., 2013). Alcohol use has been identified as the third-leading risk 
factor for the global burden of disease and injury. Excessive alcohol consumption is 
estimated to drive costs of over $200 billion annually in the USA. Varenicline, which goes 
N=1000 Independent covariates Correlated covariates Ratios: Corr::Indpndt Diff: Corr-Indpndt
PCD MSE Corr0 Incorr0 Exact PCD MSE Corr0 Incorr0 Exact PCD MSE Corr0 Incorr0 Exact
Y1.A.EN 97.7 0.046 6.90 0 0.91 95.8 0.053 6.39 0 0.61 0.98 1.16 0.93 0.00 (0.30)
Y1.A.L 97.5 0.045 6.97 0 0.97 95.6 0.051 6.77 0 0.82 0.98 1.12 0.97 0.00 (0.15)
Y1.B.EN 97.6 0.054 6.97 0 0.98 94.5 0.070 6.38 0 0.55 0.97 1.30 0.92 0.00 (0.43)
Y1.B.L 97.4 0.054 7.00 0 1.00 94.0 0.072 6.75 0 0.79 0.97 1.34 0.96 0.00 (0.21)
Y1.C.EN 97.5 0.045 6.99 0 0.99 94.9 0.057 6.73 0 0.74 0.97 1.27 0.96 0.00 (0.25)
Y1.C.L 97.3 0.045 7.00 0 1.00 94.5 0.056 6.96 0 0.97 0.97 1.26 0.99 0.00 (0.03)
Y1.D.EN 97.9 0.041 6.93 0 0.94 96.3 0.047 6.58 0 0.63 0.98 1.16 0.95 0.00 (0.31)
Y1.D.L 97.7 0.041 6.99 0 0.99 95.9 0.048 6.92 0 0.92 0.98 1.17 0.99 0.00 (0.07)
Y1.EN 98.4 0.036 6.92 0 0.93 97.2 0.039 6.33 0 0.55 0.99 1.09 0.91 0.00 (0.38)
Y1.L 98.3 0.035 6.99 0 0.99 97.0 0.038 6.84 0 0.86 0.99 1.10 0.98 0.00 (0.13)
Y2.A.EN 95.7 0.085 6.94 0 0.94 92.6 0.090 6.60 0 0.64 0.97 1.06 0.95 0.00 (0.30)
Y2.A.L 95.4 0.082 7.00 0 1.00 92.3 0.086 6.83 0 0.84 0.97 1.05 0.98 0.00 (0.16)
Y2.B.EN 94.9 0.099 6.98 0 0.98 91.1 0.112 6.59 0.02 0.65 0.96 1.13 0.94 0.02 (0.33)
Y2.B.L 94.5 0.098 7.00 0 1.00 90.3 0.113 6.78 0.1 0.75 0.96 1.16 0.97 0.10 (0.25)
Y2.C.EN 94.8 0.084 6.99 0 0.99 92.2 0.092 6.64 0 0.68 0.97 1.09 0.95 0.00 (0.31)
Y2.C.L 94.2 0.085 6.99 0 0.99 91.2 0.093 6.88 0.02 0.87 0.97 1.10 0.98 0.02 (0.12)
Y2.D.EN 96.4 0.066 6.96 0 0.96 94.8 0.069 6.59 0 0.67 0.98 1.05 0.95 0.00 (0.29)
Y2.D.L 96.0 0.067 7.00 0 1.00 94.5 0.069 6.83 0 0.85 0.98 1.02 0.98 0.00 (0.15)
Y2.EN 96.7 0.064 6.98 0 0.98 95.3 0.064 6.54 0 0.67 0.99 1.00 0.94 0.00 (0.31)
Y2.L 96.4 0.063 6.99 0 0.99 95.2 0.061 6.83 0 0.90 0.99 0.97 0.98 0.00 (0.09)
Y3.A.EN 96.4 0.070 6.91 0 0.91 93.0 0.085 6.57 0 0.66 0.96 1.22 0.95 0.00 (0.25)
Y3.A.L 96.1 0.070 6.99 0 0.99 92.6 0.084 6.80 0.01 0.81 0.96 1.21 0.97 0.01 (0.18)
Y3.B.EN 96.1 0.082 7.00 0 1.00 91.3 0.110 6.58 0.08 0.62 0.95 1.34 0.94 0.08 (0.38)
Y3.B.L 95.8 0.081 7.00 0 1.00 90.8 0.108 6.77 0.13 0.70 0.95 1.33 0.97 0.13 (0.30)
Y3.C.EN 95.9 0.074 6.98 0 0.98 91.8 0.095 6.67 0 0.76 0.96 1.30 0.96 0.00 (0.22)
Y3.C.L 95.7 0.070 6.98 0 0.98 91.0 0.096 6.83 0 0.87 0.95 1.39 0.98 0.00 (0.11)
Y3.D.EN 96.9 0.062 6.96 0 0.96 94.5 0.076 6.68 0 0.73 0.98 1.22 0.96 0.00 (0.23)
Y3.D.L 96.6 0.062 6.99 0 0.99 94.1 0.076 6.93 0 0.93 0.97 1.22 0.99 0.00 (0.06)
Y3.EN 97.4 0.054 6.93 0 0.94 95.6 0.061 6.49 0 0.62 0.98 1.13 0.94 0.00 (0.32)
Y3.L 97.2 0.053 6.98 0 0.98 95.2 0.062 6.88 0 0.88 0.98 1.16 0.99 0.00 (0.10)
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by the trade name Chantix, was approved by the US Food and Drug Administration in 2006 
as an aid for smoking cessation. Varenicline is an 𝛼4𝛽2 nicotinic acetylcholine agonist. 
Converging lines of research suggest that both alcohol and nicotine affect nicotinic 
acetylcholine receptors, which control rewarding effects in the brain. Since varenicline has 
proven effective at aiding smoking cessation, and since alcohol appears to affect the brain 
in a similar fashion as nicotine, it seems reasonable that this same drug may show benefit 
in aiding drinking cessation, or at least drinking reduction. 
The target population consisted of adults at least 18 years old who were consistent 
heavy drinkers (defined as at least 28 drinks per week for females, or at least 35 drinks per 
week for males). Exclusion criteria included being pregnant, being addicted to any drugs 
other than alcohol or nicotine, having any psychiatric disorders, and certain other 
comorbidities. The study design was a Phase II randomized, double-blind, placebo-
controlled multisite trial, and the duration of the study period was 13 weeks. Ultimately 99 
subjects were enrolled in the treatment arm, and 101 subjects were enrolled in the control 
arm. Three subjects in the treatment group had insufficient outcome data for analysis. Table 










N (%) 101 (51.3) 96 (48.7)
Mean (s.d.) Mean (s.d.)
Age 45.0 (12.3) 46.0 (11.0)
Years education 14.8 (2.7) 14.4 (3.1)
FTND 3.1 (2.6) 3.0 (2.4)
Baseline CIWA 1.3 (1.7) 1.3 (1.5)
Baseline Avg. SDUs 12.5 (8.9) 14.3 (9.3)
Baseline DPDD 13.6 (9.0) 15.4 (9.6)
Baseline % Days Abstained 0.1 (0.1) 0.1 (0.1)
Baseline % HDD 0.9 (0.2) 0.9 (0.2)
Baseline % VHDD 0.6 (0.4) 0.7 (0.4)
Baseline PACS 16.7 (6.8) 17.7 (6.2)
LTDH 25.7 (12.6) 27.3 (11.8)
N (%) N (%)
Gender
Female 32 (31.7) 25 (26.0)
Male 69 (68.3) 71 (74.0)
Employment status    
Unemp./Ret. 20 (19.8) 24 (25.0)
Part-time 23 (22.8) 17 (17.7)
Full-time 58 (57.4) 55 (57.3)
Marital status    
With partner* 43 (42.6) 46 (47.9)
Without partner** 58 (57.4) 50 (52.1)
Race    
Asian or Other 1 (1.0) 7 (7.3)
Black 27 (26.7) 30 (31.3)
White 73 (72.3) 59 (61.5)
Ethnicity    
Hispanic/Latino 2 (2.0) 2 (2.1)
Not Hispanic/Latino 99 (98.0) 94 (97.9)
Current smoker
No 60 (59.4) 59 (61.5)
Yes 41 (40.6) 37 (38.5)
Goal: Abstinence#
No 73 (72.3) 69 (71.9)
Yes 28 (27.7) 27 (28.1)
Family hist.##
No 34 (33.7) 27 (28.1)
Yes 67 (66.3) 69 (71.9)
**Without partner includes divorced, never married, separated, and widowed.
#Goal:Abstinence: subject's indicated alcohol-related goal from the study was abstinence


























FTND: Fagerstrom Test for Nicotine Dependence score; CIWA: Clinical Institute 
Withdrawal Assessment of Alcohol score; SDU: Standard Drink Unit; DPDD: Drinks Per 
Drinking Day; HDD: Heavy Drinking Day; VHDD: Very Heavy Drinking Day; PACS: Penn 
Alcohol Craving Scale score; LTDH: Lifetime Drinking History (years)
*With partner includes legally married and living with partner/cohabiting
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4.4.2 Case study results 
Figure 4.2 displays, for each study arm, the 7-day moving average of standard drink 
units (SDUs2) reported by study subjects for the time period ranging from 90 days pre-
study through the full 91-day (13 week) study period. It is evident that, on average across 
all subjects in the respective groups, substantial reductions in drinking occurred during the 
study period. The fact that the decrease is apparent for the placebo arm as well as the 
treatment arm is of primary interest and highlights the question of how much of the change 
is actual treatment effect from varenicline versus placebo effect driven by, for example, 
heightened attention to consumption quantities or enhanced commitment to drinking 
reduction goals, both consequences merely of being in the study. 
 
Figure 4.2: Case study outcome data, pre-study and 13-week study period 
 
In the current analysis of the case study data, the outcome measure was the change 
in average SDUs per day, comparing between the 28-day pre-study period and the three-
month post-titration study period. Figure 4.2 suggests a somewhat greater magnitude drop 
 
 
2 The SDU metric standardizes the measurement of alcohol serving across various types of drinks, such as 
beer, wine, and liquor. 
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in average SDUs for the treatment group. Indeed, a simple comparison of the difference in 
the before-after change in average SDUs between the placebo arm and the treatment arm 
shows a statistically significant difference (estimated group difference = -2.31 SDUs, t-
statistic = -2.01, p-value [one-sided test with 95 d.f.] = 0.024). 
While this result is of interest, it remains that the magnitude of the treatment effect 
is fairly modest. An additional research question is whether there exists any subgroup of 
the study population for which the treatment effect is substantially different from the 
overall ATE. Thus we applied the method described in Section 4.2 to the case study data 
in order to identify any such subgroups. For the probability of treatment group membership 
(step (i) in Section 4.2), we used 0.5, since the data were from a randomized controlled 
trial and the balance of sample size and covariates across treatment arms was generally 
quite good. For step (ii), we again used generalized boosted modeling, as in the simulation 
study. In estimating the g-function (i.e., those covariates that interact with treatment in 
affecting the outcome, step (iii)), we employed a design matrix that included covariate 
main effects and 2-way covariate interactions and used elastic net for selecting predictor 
variables. Two subgroups were identified via the method, one involving the interaction of 
two binary covariates, the other a single categorical covariate. After the covariates were 
selected into the g-function, we estimated the treatment effects for the defined subgroups 
using an ordinary linear regression model with only the treatment arm indicator and the 
selected covariates. 
Table 4.4 summarizes the two groups and the estimated ATE for the groups and 
their complements, illustrating the differing treatment effects of the group membership. 
The first identified subgroup was defined based on two binary covariates. In pre-study 
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screening, patients were interviewed as to their personal goals with respect to alcohol 
consumption from participation in the study. The first covariate was a binary indicator 
coding whether the subject stated their goal was to “achieve total abstinence” (N=56, 
28.4%) or something else (N=141, 71.6%). The second covariate was a binary indicator 
coding whether the subject indicated in the pre-study questionnaire that they had had any 
family member who had a history of alcohol problems (N=136, 69%). This first subgroup, 
then, was defined as those subjects who both had a goal of total abstinence and had a family 
member with a history of alcohol problems (N=48, 24.4%). The estimated treatment effect 
for members of this subgroup was a before-after drop in SDUs that was 5.8 SDUs greater 
than subjects not in the group (see Table 4.4; avg. SDU difference of -15.3 vs. -8.6 for 
treatment and control arms, respectively, for members of the subgroup; avg. SDU 
difference of -7.0 vs. -6.1 for treatment and control arms, respectively, for subjects not in 
the subgroup). 
Table 4.4: Subgroups identified in varenicline case study 
 
 
The second identified subgroup was defined as those whose household income was 
less than or equal to $15,000 per year. In this case, members of the subgroup realized less 
ARM=Placebo ARM=Varenicline
GROUP # (%) obs in grp Mean (s.d.) Mean (s.d.) ATE
A 48 (24%) -8.6 (4.7) -15.3 (12.3) -6.7
Ac 149 (76%) -6.1 (8.5) -7.0 (5.3) -0.9
B 25 (13%) -16.3 (15.0) -9.7 (5.4) 6.6
Bc 172 (87%) -5.7 (5.7) -8.9 (8.7) -3.2
Notes: Superscript c indicates the complement of the group.
Group definitions:
A: Goal_abstain=1 and Fam_alc_hist=1
B: Household income <= $15,000
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benefit from the study drug: the estimated treatment effect in the subgroup was +6.6 SDUs, 
while for those not in the subgroup it was -3.2 SDUs. 
 
4.5 Conclusions 
This chapter presents a method for identifying covariates that interact with a binary 
treatment to affect the outcome, hence characterizing subgroups of a study population that 
have differing average treatment effects. The method is capable of handling a large number 
of covariates, due to the complexity control exerted by way of penalized regression. Also, 
the method is capable of handling both experimental data and observational data; a simple 
change from using an assumed known probability of treatment group membership to using 
a modeled probability is all that is required. In a simulation study, it performed strongly in 
correctly deciding whether to assign particular subjects to treatment or control, based on 
their covariates.  
This work does have some limitations. So far, it applies only to point-in-time 
treatments. Extending this work to dynamic treatment regimens would be beneficial, 
particularly given that individualized treatment regimes are receiving heightened attention 
in today’s push toward personalized medicine. Also, the method should be studied for its 
effectiveness with binary or categorical outcomes, as the work to date has focused on 
continuous outcome measures. The characterization of the subgroups resulting from the 
selected covariates is not automatic, but a separate step following the method. 
Nevertheless, this approach appears flexible and powerful for selecting predictor variables 
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A1 Appendix 1: Proofs of theorems in Chapter 2 
Proof of Theorem 1 for exchangeability 
i. 𝑇 ⊥ (𝑌( ), 𝑌( ))|𝑋 , since 𝑋  blocks the backdoor path from 𝑇 to 𝑌.  
ii. 𝑇 ⊥ (𝑌( ), 𝑌( ))|(𝑋 , 𝑋 ) can be obtained from the following: 
𝑓 𝑌( ), 𝑌( ), 𝑇|𝑋 , 𝑋 =
𝑓 𝑌( ), 𝑌( ), 𝑇, 𝑋 , 𝑋  
𝑓(𝑋 , 𝑋 )
 
=
𝑓 𝑌( ), 𝑌( )|𝑋  𝑓(𝑇, 𝑋 |𝑋  )𝑓(𝑋 )
𝑓(𝑋 , 𝑋 )
                            𝑏𝑦 (𝑋 , 𝑇)⟘(𝑌( ), 𝑌( ))|𝑋  
=
𝑓 𝑌( ), 𝑌( )|𝑋 ,  𝑋   𝑓(𝑇| 𝑋 , 𝑋  )𝑓(𝑋 |𝑋 )𝑓(𝑋 )
𝑓(𝑋 , 𝑋 )
          𝑏𝑦 𝑋 ⟘(𝑌( ), 𝑌( ))|𝑋  
= 𝑓 𝑌( ), 𝑌( )|𝑋 , 𝑋  𝑓(𝑇| 𝑋 , 𝑋  ) 
iii. 𝑇 ⊥ (𝑌( ), 𝑌( ))|(𝑋 , 𝑋 ) can be obtained from the following: 
𝑓 𝑌( ), 𝑌( ), 𝑇|𝑋 , 𝑋  
=
𝑓 𝑌( ), 𝑌( ),   𝑇,   𝑋 ,   𝑋  
𝑓(𝑋 , 𝑋 )
 
=
𝑓 𝑋 , 𝑌( ), 𝑌( )|𝑋  𝑓(𝑇|𝑋  )𝑓(𝑋 )
𝑓(𝑋 , 𝑋 )





𝑓 𝑌( ), 𝑌( )|𝑋 ,   𝑋  𝑓(𝑋 |𝑋 )𝑓(𝑇| 𝑋 , 𝑋  )𝑓(𝑋 )
𝑓(𝑋 , 𝑋 )
            𝑏𝑦 𝑇 ⊥ 𝑋 |𝑋  
= 𝑓 𝑌( ), 𝑌( )|𝑋 , 𝑋  𝑓(𝑇| 𝑋 , 𝑋  ) 
iv. 𝑇 ⊥ (𝑌( ), 𝑌( ))|(𝑋 , 𝑋 , 𝑋 ) can be obtained from the following: 
𝑓 𝑌( ), 𝑌( ), 𝑇|𝑋 , 𝑋 , 𝑋  
=
𝑓 𝑌( ), 𝑌( ), 𝑇, 𝑋 , 𝑋 , 𝑋  
𝑓(𝑋 , 𝑋 , 𝑋 )
 
=
𝑓 𝑋 , 𝑌( ), 𝑌( )|𝑋  𝑓(𝑋 , 𝑇|𝑋  )𝑓(𝑋 )
𝑓(𝑋 , 𝑋 , 𝑋 )
                     𝑏𝑦 (𝑋 , 𝑇) ⊥ (𝑋 , 𝑌( ), 𝑌( ))|𝑋  
=
𝑓 𝑌( ), 𝑌( )|𝑋 , 𝑋  𝑓(𝑋 |𝑋 )𝑓(𝑇| 𝑋 , 𝑋  )𝑓(𝑋 |𝑋 )𝑓(𝑋 )
𝑓(𝑋 , 𝑋 , 𝑋 )
 
=
𝑓 𝑌( ), 𝑌( )|𝑋 , 𝑋 , 𝑋  𝑓(𝑋 |𝑋 )𝑓(𝑇| 𝑋 , 𝑋 , 𝑋  )𝑓(𝑋 |𝑋 )𝑓(𝑋 )
𝑓(𝑋 , 𝑋 , 𝑋 )
 
= 𝑓 𝑌( ), 𝑌( )|𝑋 , 𝑋 , 𝑋  𝑓(𝑇| 𝑋 , 𝑋 , 𝑋  ) 
The second-to-last equation is due to 𝑋 ⊥ (𝑌( ), 𝑌( ))|𝑋 , 𝑋 =
𝑓 𝑌( ), 𝑌( ) 𝑋 , 𝑋 , 𝑋 𝑓(𝑇|𝑋 , 𝑋 , 𝑋 ). 
 
Proof of Theorem 1 for unbiasedness of ATE estimators:  
Let 𝑋(∗) represent any one of the adjustment sets (i) 𝑋 ; (ii) 𝑋 , 𝑋 ; (iii) 𝑋 , 𝑋 ; or (iv) 
𝑋 , 𝑋 , 𝑋 . Under the assumptions of exchangeability (i.e., T⟘(𝑌( ), 𝑌( ))|𝑋(∗)) and 
positivity (i.e., 0 < 𝑃 𝑌 = 1 𝑋(∗) = 𝑝 𝑿(∗) < 1), we claim that the IPW estimator for 
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(∗) 𝐸 𝑌( )|𝑿(∗)          𝑏𝑦 𝑒𝑥𝑐ℎ𝑎𝑛𝑔𝑒𝑎𝑏𝑖𝑙𝑖𝑡𝑦  
                         = 𝐸
1
𝑝(𝑿(∗))
𝑝(𝑿(∗))𝐸 𝑌( )|𝑿(∗) = 𝐸 𝐸 𝑌( )|𝑿(∗) = 𝐸 𝑌( )  
Similarly, under exchangeability, we have 𝐸
( )
𝑿(∗)
= 𝐸 𝑌( ) .  
Thus 𝐸 ?̂?(∗) = 𝐸 𝑌( ) − 𝐸 𝑌( ) = 𝜏. 
 
Proof of Theorem 2(i): Note that under Proposition 1, 𝑋 ⊥ ( 𝑌( ), 𝑌( ))|(𝑋 , 𝑋 ), so we 
have 𝐸 𝑌( )|𝑋 , 𝑋 , 𝑋  = 𝐸 𝑌( )|𝑋 , 𝑋  , 𝐸 𝑌( )|𝑋 , 𝑋 , 𝑋  = 𝐸 𝑌( )|𝑋 , 𝑋  , 
𝜎 (𝑋 , 𝑋 , 𝑋 ) = 𝜎 (𝑋 , 𝑋 ),  and 𝜎 (𝑋 , 𝑋 , 𝑋 ) = 𝜎 (𝑋 , 𝑋 ). The first two equations 
imply that 𝜏(𝑋 , 𝑋 ) = 𝜏(𝑋 , 𝑋 , 𝑋 ).  Thus, 
𝐸
𝜎 (𝑋 , 𝑋 , 𝑋 )
𝑝(𝑋 , 𝑋 , 𝑋 )
= 𝐸 𝐸
𝜎 (𝑋 , 𝑋 , 𝑋 )
𝑝(𝑋 , 𝑋 , 𝑋 )
|𝑋 , 𝑋
= 𝐸 𝜎 (𝑋 , 𝑋 )𝐸
1
𝑝(𝑋 , 𝑋 , 𝑋 )
|𝑋 , 𝑋
≥ 𝐸 𝜎 (𝑋 , 𝑋 )
1
𝐸 𝑝(𝑋 , 𝑋 , 𝑋 ) (𝑋 , 𝑋 )





𝜎 (𝑋 , 𝑋 )
𝑝(𝑋 , 𝑋 )
. 
Similarly, we have  
𝐸
𝜎 (𝑋 , 𝑋 , 𝑋 )
1 − 𝑝(𝑋 , 𝑋 , 𝑋 )
≥ 𝐸
𝜎 (𝑋 , 𝑋 )
1 − 𝑝(𝑋 , 𝑋 )
. 
In addition, we have 
𝐸[(𝜏(𝑋 , 𝑋 ) − 𝜏) ] = 𝐸[(𝜏(𝑋 , 𝑋 , 𝑋 ) − 𝜏) ]. 
Thus, we have proved the first inequality in (i). For the second inequality in (i), note that 
𝑝(𝑋 , 𝑋 , 𝑋 ) = 𝑝(𝑋 , 𝑋 ). Thus, 
𝐸
𝜎 (𝑋 , 𝑋 , 𝑋 )
𝑝(𝑋 , 𝑋 , 𝑋 )
= 𝐸 𝐸
𝐸 (𝑌( )) |𝑋 , 𝑋 , 𝑋 − 𝐸 𝑌( )|𝑋 , 𝑋 , 𝑋
𝑝(𝑋 , 𝑋 , 𝑋 )
|𝑋 , 𝑋
= 𝐸
𝐸 𝑌( ) 𝑋 , 𝑋 − 𝐸 𝐸 𝑌( )|𝑋 , 𝑋 , 𝑋 |𝑋 , 𝑋
𝑝(𝑋 , 𝑋 )
≤ 𝐸
𝐸 𝑌( ) 𝑋 , 𝑋 − 𝐸 𝑌( )|𝑋 , 𝑋
𝑝(𝑋 , 𝑋 )
= 𝐸
𝜎 (𝑋 , 𝑋 )
𝑝(𝑋 , 𝑋 )
. 
The last inequality is from using Jensen’s Inequality: 𝐸 𝐸 𝑌( )|𝑋 , 𝑋 , 𝑋 |𝑋 , 𝑋 ≥
𝐸 𝐸 𝑌( )|𝑋 , 𝑋 , 𝑋 |𝑋 , 𝑋 = 𝐸 𝑌( )|𝑋 , 𝑋 . 
Similarly, we can prove that  𝐸
( , , )




. In addition, due to omitting 




𝐸[(𝜏(𝑋 , 𝑋 , 𝑋 ) − 𝜏) ] ≤ 𝐸[(𝜏(𝑋 , 𝑋 ) − 𝜏) ]. 
Thus, the second inequality holds. 
 
Proof of Theorem 2(ii):  The first inequality is straightforward, since  𝑝(𝑋 , 𝑋 ) =
P(𝑇 = 1|𝑋 , 𝑋 ) = P(𝑇 = 1|𝑋 ) = 𝑝(𝑋 ). We also expect 𝐸𝜎 (𝑋 , 𝑋 ) ≤ 𝐸𝜎 (𝑋 ), 
𝜎 (𝑋 , 𝑋 ) ≤ 𝐸𝜎 (𝑋 ), and  
𝐸[(𝜏(𝑋 , 𝑋 ) − 𝜏) ] ≤ 𝐸[(𝜏(𝑋 ) − 𝜏) ]. 
The second inequality in (ii) holds due to the following argument: 
𝐸
𝜎 (𝑋 , 𝑋 )
𝑝(𝑋 , 𝑋 )
= 𝐸 𝐸
𝐸 (𝑌( )) |𝑋 , 𝑋 − 𝐸 𝑌( )|𝑋 , 𝑋
𝑝(𝑋 , 𝑋 )
|𝑋
= 𝐸 𝐸
𝐸 (𝑌( )) |𝑋 − 𝐸 𝑌( )|𝑋
𝑝(𝑋 , 𝑋 )
|𝑋
= 𝐸 𝐸 (𝑌( )) |𝑋 − 𝐸 𝑌( )|𝑋 𝐸
1
𝑝(𝑋 , 𝑋 )
|𝑋
≥ 𝐸 𝐸 𝑌( ) |𝑋 − 𝐸 𝑌( )|𝑋
1











, and 𝐸(𝜏(𝑋 , 𝑋 ) − 𝜏) =





A2 Appendix 2: Boxplots (all scenarios) and tables (correlated scenarios) of simulation study results 
 
Figure A2.1. Box plots of ATE estimates in simulation study 





Table A2.1. Bias, Standard Error, and Root MSE for Correlated Simulation Scenario 
𝜌 = 𝜌 = 𝜌 = 0.2 
 
Figure A2.2. Box plots of ATE estimates in simulation study 
Moderate correlation: 𝜌 = 𝜌 = 𝜌 = 0.2 
REFERENCE MODELS
# SCENARIO EN0 EN0.5 EN0.7 EN1 EN.opt OAL CB.over CB.just EN.CB.o EN.CB.j XC X CX P XCXI XCXPXI XCXPXIXS
Model A: Bias 0.001 0.003 0.002 0.001 0.003 0.003 0.029 -0.007 0.016 -0.006 0.002 0.001 0.004 0.003 0.001
8 SE 0.065 0.032 0.030 0.029 0.034 0.034 0.044 0.048 0.031 0.033 0.032 0.029 0.065 0.063 0.065
n/p=50 RMSE 0.065 0.033 0.030 0.029 0.034 0.034 0.052 0.049 0.035 0.034 0.032 0.029 0.065 0.063 0.065
Model A: Bias * 0.005 0.005 0.005 0.004 * * * 0.029 -0.006 0.004 0.004 0.010 0.010 *
9 SE * 0.043 0.042 0.041 0.042 * * * 0.040 0.042 0.047 0.042 0.089 0.086 *
n/p=0.833 RMSE * 0.043 0.042 0.042 0.043 * * * 0.049 0.042 0.047 0.042 0.090 0.087 *
Model A: Bias -0.009 0.004 0.004 0.003 0.004 0.016 0.085 0.054 0.025 -0.006 0.003 0.003 0.004 0.005 -0.009
10 SE 0.206 0.044 0.043 0.043 0.043 0.049 0.064 0.064 0.041 0.044 0.047 0.042 0.084 0.082 0.206





Table A2.2. Bias, Standard Error, and Root MSE for Correlated Simulation Scenario 




Figure A2.3. Box plots of ATE estimates in simulation study 
Strong correlation: 𝜌 = 𝜌 = 𝜌 = 0.5
REFERENCE MODELS
# SCENARIO EN0 EN0.5 EN0.7 EN1 EN.opt OAL CB.over CB.just EN.CB.o EN.CB.j XC X C X P XCXI XCXPXI XCXPXIXS
Model A: Bias 0.009 0.007 0.006 0.006 0.007 0.009 0.036 -0.006 0.022 -0.002 0.007 0.006 0.011 0.010 0.009
11 SE 0.077 0.035 0.032 0.030 0.038 0.035 0.049 0.052 0.033 0.033 0.034 0.029 0.075 0.073 0.077
n/p=50 RMSE 0.078 0.035 0.033 0.031 0.039 0.036 0.061 0.052 0.039 0.033 0.034 0.030 0.076 0.074 0.078
Model A: Bias * 0.005 0.006 0.005 0.005 * * * 0.031 -0.006 0.006 0.005 0.016 0.015 *
12 SE * 0.045 0.044 0.043 0.044 * * * 0.043 0.044 0.049 0.043 0.098 0.095 *
n/p=0.833 RMSE * 0.046 0.045 0.044 0.045 * * * 0.053 0.045 0.049 0.043 0.099 0.097 *
Model A: Bias -0.008 0.005 0.005 0.004 0.005 0.017 0.102 0.069 0.028 -0.007 0.002 0.003 0.015 0.016 -0.008
13 SE 0.217 0.045 0.044 0.041 0.045 0.049 0.065 0.062 0.041 0.044 0.046 0.041 0.094 0.093 0.217





A3 Appendix 3: Derivation of posterior conditional distributions, Chapter 3 
This portion specifies the model, all prior distributions, the full joint posterior distribution, 
and the conditional posterior distribution for each parameter. 
Model:  
𝑌 |𝑇 ~
𝑁𝑜𝑟𝑚𝑎𝑙(𝜃 + 𝜏, 𝑝 𝜎 ), 𝑖𝑓 𝑇 = 1
𝑁𝑜𝑟𝑚𝑎𝑙(𝜃, (1 − 𝑝 )𝜎 ), 𝑖𝑓 𝑇 = 0
 
𝑇 |𝑝 ~𝐵𝑒𝑟𝑛𝑜𝑢𝑙𝑙𝑖(𝑝 ) 
𝜏~𝑁𝑜𝑟𝑚𝑎𝑙(0, 𝜎 ) 
𝜃~𝑁𝑜𝑟𝑚𝑎𝑙 0, 𝜎  
𝜎 ~𝐼𝑛𝑣. 𝐺𝑎𝑚𝑚𝑎(𝑎, 𝑏) 
𝑝 |𝛼 , 𝜆~𝐵𝑒𝑡𝑎(𝜆𝛼 , 𝜆) 
𝛼 |𝛽, 𝜈 ~𝐿𝑜𝑔𝑛𝑜𝑟𝑚𝑎𝑙(𝑥 𝛽, 𝜈 ) 
𝛽~𝑀𝑢𝑙𝑡𝑖𝑣𝑎𝑟. 𝑁𝑜𝑟𝑚𝑎𝑙 0, Σ  






Now we detail the full joint posterior distribution for the data and all of the parameters: 
 
Data = 𝒟 = {𝑦, 𝑥, 𝑡} 
Parameters = 𝛩 = {𝜏, 𝜃, 𝜎 , 𝑝, 𝛼, 𝛽, 𝜈 , 𝜆} 
Fixed settings/hyperparameters = 𝒫 = 𝜎 , 𝜎 , 𝛴 , 𝑎, 𝑏, 𝑐, 𝑑, 𝑓, 𝑔  
Full joint posterior: 𝑓(𝑦 ∣ 𝑡, 𝛩, 𝒟)𝑓(𝑡 ∣ 𝛩, 𝒟)𝜋(𝛩) 
𝑓(𝑦 ∣ 𝑇, 𝛩, 𝒟) =
exp − ∑
𝑇 (𝑦 − 𝜏 − 𝜃)
2𝑝 𝜎
+
(1 − 𝑇 )(𝑦 − 𝜃)
2(1 − 𝑝 )𝜎
𝜎 (√2𝜋) ∏ (1 − 𝑝 ) 𝑝
 


























(1 − 𝑝 )( ) 
𝜋(𝛼 ∣ 𝛽, 𝜈 ) =
1
√2𝜋𝜈
(𝛼 ) exp −
































Now we detail the conditional posterior distributions for each of the parameters: 
 






















(1 − 𝑇 )
(1 − 𝑝 )𝜎
 and 
𝑀 . = 𝑉 . ∑
𝑇 (𝑦 − 𝜏)
𝑝 𝜎
+
(1 − 𝑇 )𝑦




𝜋(𝜎 ∣. ) ∝ Inv. Gamma
𝑛
2
+ 𝑎, 𝑏 +
𝑇 (𝑦 − 𝜏 − 𝜃)
2𝑝
+
(1 − 𝑇 )(𝑦 − 𝜃)
2(1 − 𝑝 )
. 
 
𝜋(𝑝 ∣. ) ∝ 𝑝 (1 − 𝑝 )
( )
exp −
𝑇 (𝑦 − 𝜏 − 𝜃)
2𝜎 𝑝
+
(1 − 𝑇 )(𝑦 − 𝜃)
2𝜎 (1 − 𝑝 )
. 
 












𝜋(𝛽 ∣. ) ∝ MVN 𝛽, 𝑉 . , where 
𝑉 . = 𝑋 𝑉 𝑋 + 𝛴 ,
𝑉 = 𝜈 𝐼 , and
𝛽 = 𝑉 . (𝑋 𝑉 𝛼).
 
 
𝜋(𝜈 ∣. ) ∝ Inv. Gamma
𝑛
2
+ 𝑐, 𝑑 +














The posterior conditional distributions for five of these parameters (𝜏, 𝜃, 𝜎 , 𝛽, and 𝜈 ) are 
known distributions, and hence we may obtain posterior samples via Gibbs sampling. The 
other three parameters (𝑝, 𝛼, and 𝜆) are complex, unknown distributions. Hence we will 
use the Metropolis-Hastings (MH) algorithm to obtain posterior condition samples for 





For 𝜋(𝑝 ∣. ), we have 
log[𝜋(𝑝 ∣. )] ∝
𝑇
2
+ 𝜆𝛼 − 1 log𝑝 +
(1 − 𝑇 )
2
+ 𝜆 − 1 log(1 − 𝑝 ) −
𝑇 (𝑦 − 𝜏 − 𝜃)
2𝜎 𝑝
−
(1 − 𝑇 )(𝑦 − 𝜃)
2𝜎 (1 − 𝑝 )
.
 
For 𝜋(𝛼 ∣. ), we have 
log[𝜋(𝛼 ∣. )] ∝ log[𝛤(𝜆𝛼 + 𝜆)] − log[𝛤(𝜆𝛼 )] − log[𝛤(𝜆)] +
(𝜆𝛼 − 1)log𝑝 − log𝛼 −




Finally for 𝜋(𝜆 ∣. ), we have 
log[𝜋(𝜆 ∣. )] ∝ {log[𝛤(𝜆𝛼 + 𝜆)] − log[𝛤(𝜆𝛼 )] − log[𝛤(𝜆)] +
(𝜆𝛼 − 1)log𝑝 + (𝜆 − 1)log(1 − 𝑝 )} +









A4 Appendix 4: Alternative Bayesian model formulation using weighted likelihood 
Here we present an alternative formulation of the Bayesian model. This approach has the 
appeal that it is somewhat less complex than the approach described in the main body of 
the article, with less parameterizations involved. This approach uses a weighted likelihood. 
We assume the following distributions for the data 𝑌  and 𝑇 : 
𝑌 |𝑇 ~
𝑁𝑜𝑟𝑚𝑎𝑙(𝜃 + 𝜏, 𝜎 ), 𝑖𝑓 𝑇 = 1
𝑁𝑜𝑟𝑚𝑎𝑙(𝜃, 𝜎 ), 𝑖𝑓 𝑇 = 0
 
𝑇 |𝑝 ~𝐵𝑒𝑟𝑛𝑜𝑢𝑙𝑙𝑖 𝑒𝑥𝑝𝑖𝑡(𝑥 𝛽) , 




𝜏~𝑁𝑜𝑟𝑚𝑎𝑙(0, 𝜎 ), 
𝜃~𝑁𝑜𝑟𝑚𝑎𝑙 0, 𝜎 , 
𝜎 ~𝐼𝑛𝑣. 𝐺𝑎𝑚𝑚𝑎(𝑎, 𝑏), 
and 
𝛽|𝜈 ~𝑀𝑢𝑙𝑡𝑖𝑣𝑎𝑟. 𝑁𝑜𝑟𝑚𝑎𝑙 0, 𝜈 ∗ 𝐼 . 












A5 Appendix 5: Tables of additional simulation results, Chapter 4 
Table A5.1 Subgroup analysis simulation study results (N=400) 
 
 
Table A5.2 Subgroup analysis simulation study results (N=200) 
 
  
N=400 Independent covariates Correlated covariates Ratios: Corr::Indpndt Diff: Corr-Indpndt
PCD MSE Corr0 Incorr0 Exact PCD MSE Corr0 Incorr0 Exact PCD MSE Corr0 Incorr0 Exact
Y1.A.EN 95.76 0.102 6.89 0 0.90 92.7 0.118 6.29 0 0.48 0.97 1.16 0.91 0.00 (0.42)
Y1.A.L 95.36 0.102 6.99 0 0.99 92.4 0.115 6.64 0.02 0.70 0.97 1.13 0.95 0.02 (0.29)
Y1.B.EN 94.68 0.121 6.90 0 0.91 90.5 0.149 6.40 0.14 0.51 0.96 1.23 0.93 0.14 (0.40)
Y1.B.L 94.35 0.117 6.94 0 0.96 90.2 0.144 6.68 0.19 0.61 0.96 1.23 0.96 0.19 (0.35)
Y1.C.EN 95.64 0.102 6.89 0 0.92 91.6 0.124 6.46 0.04 0.57 0.96 1.22 0.94 0.04 (0.35)
Y1.C.L 95.19 0.100 6.99 0 0.99 91.0 0.123 6.72 0.06 0.70 0.96 1.22 0.96 0.06 (0.29)
Y1.D.EN 95.72 0.097 6.82 0 0.85 93.7 0.110 6.38 0 0.51 0.98 1.13 0.94 0.00 (0.34)
Y1.D.L 95.43 0.096 6.92 0 0.93 93.5 0.107 6.63 0 0.67 0.98 1.12 0.96 0.00 (0.26)
Y1.EN 96.74 0.090 6.79 0 0.83 95.1 0.093 6.09 0 0.41 0.98 1.04 0.90 0.00 (0.42)
Y1.L 96.48 0.088 6.91 0 0.93 94.7 0.094 6.69 0 0.74 0.98 1.06 0.97 0.00 (0.19)
Y2.A.EN 89.42 0.169 6.93 0.08 0.89 87.9 0.175 6.34 0.34 0.39 0.98 1.03 0.91 0.26 (0.50)
Y2.A.L 89.34 0.165 6.96 0.08 0.90 87.5 0.171 6.55 0.43 0.39 0.98 1.03 0.94 0.35 (0.51)
Y2.B.EN 85.52 0.194 6.84 0.45 0.63 82.6 0.215 6.52 0.99 0.17 0.97 1.11 0.95 0.54 (0.46)
Y2.B.L 84.9 0.192 6.90 0.43 0.65 84.6 0.208 6.69 1.02 0.19 1.00 1.08 0.97 0.59 (0.46)
Y2.C.EN 87.89 0.175 6.90 0.18 0.81 86.3 0.187 6.56 0.64 0.25 0.98 1.07 0.95 0.46 (0.56)
Y2.C.L 87.04 0.173 6.93 0.22 0.80 85.6 0.190 6.80 0.76 0.37 0.98 1.10 0.98 0.54 (0.43)
Y2.D.EN 92.52 0.142 6.82 0.01 0.83 90.5 0.152 6.47 0.12 0.50 0.98 1.07 0.95 0.11 (0.33)
Y2.D.L 91.9 0.138 6.92 0.03 0.89 90.0 0.150 6.73 0.14 0.63 0.98 1.08 0.97 0.11 (0.26)
Y2.EN 93.17 0.140 6.88 0 0.88 92.0 0.134 6.23 0.06 0.42 0.99 0.96 0.91 0.06 (0.46)
Y2.L 92.61 0.137 6.98 0.01 0.97 91.4 0.134 6.57 0.08 0.65 0.99 0.98 0.94 0.07 (0.32)
Y3.A.EN 92.39 0.144 6.85 0.02 0.85 87.9 0.173 6.36 0.41 0.30 0.95 1.20 0.93 0.39 (0.55)
Y3.A.L 91.53 0.143 6.90 0.01 0.91 87.4 0.172 6.67 0.51 0.37 0.95 1.20 0.97 0.50 (0.54)
Y3.B.EN 89.78 0.168 6.90 0.06 0.86 83.1 0.217 6.65 0.96 0.24 0.93 1.29 0.96 0.90 (0.62)
Y3.B.L 88.68 0.168 6.96 0.14 0.86 84.5 0.212 6.82 1.03 0.23 0.95 1.26 0.98 0.89 (0.63)
Y3.C.EN 89.9 0.157 6.92 0.11 0.86 85.9 0.190 6.76 0.58 0.38 0.96 1.21 0.98 0.47 (0.48)
Y3.C.L 88.62 0.155 6.95 0.18 0.84 84.9 0.189 6.81 0.73 0.35 0.96 1.22 0.98 0.55 (0.49)
Y3.D.EN 92.94 0.134 6.78 0 0.82 88.9 0.169 6.42 0.32 0.40 0.96 1.26 0.95 0.32 (0.42)
Y3.D.L 92.47 0.130 6.91 0.01 0.92 88.7 0.161 6.70 0.28 0.59 0.96 1.24 0.97 0.27 (0.33)
Y3.EN 94.25 0.127 6.86 0.01 0.87 91.6 0.137 6.21 0.06 0.43 0.97 1.08 0.91 0.05 (0.44)
Y3.L 93.85 0.125 6.91 0 0.92 91.2 0.134 6.55 0.08 0.65 0.97 1.07 0.95 0.08 (0.27)
N=200 Independent covariates Correlated covariates Ratios: Corr::Indpndt Diff: Corr-Indpndt
PCD MSE Corr0 Incorr0 Exact PCD MSE Corr0 Incorr0 Exact PCD MSE Corr0 Incorr0 Exact
Y1.A.EN 88.88 0.183 6.68 0.14 0.65 87.7 0.198 5.94 0.38 0.18 0.99 1.08 0.89 0.24 (0.47)
Y1.A.L 88.73 0.181 6.82 0.17 0.74 86.7 0.199 6.27 0.55 0.26 0.98 1.10 0.92 0.38 (0.48)
Y1.B.EN 87.92 0.202 6.72 0.23 0.62 81.0 0.243 6.47 1.25 0.12 0.92 1.20 0.96 1.02 (0.50)
Y1.B.L 87.7 0.196 6.81 0.22 0.70 78.9 0.242 6.55 1.43 0.09 0.90 1.24 0.96 1.21 (0.61)
Y1.C.EN 89.42 0.185 6.84 0.09 0.79 84.8 0.216 6.53 0.77 0.25 0.95 1.17 0.95 0.68 (0.54)
Y1.C.L 88.58 0.180 6.85 0.15 0.76 84.2 0.215 6.71 0.89 0.27 0.95 1.19 0.98 0.74 (0.49)
Y1.D.EN 91.54 0.180 6.68 0.07 0.70 88.2 0.198 6.19 0.42 0.25 0.96 1.10 0.93 0.35 (0.45)
Y1.D.L 90.78 0.179 6.78 0.11 0.73 88.1 0.192 6.43 0.43 0.38 0.97 1.07 0.95 0.32 (0.35)
Y1.EN 93.48 0.155 6.67 0 0.74 91.5 0.166 5.76 0.07 0.31 0.98 1.07 0.86 0.07 (0.43)
Y1.L 93.02 0.153 6.78 0.01 0.81 90.9 0.167 6.27 0.14 0.44 0.98 1.09 0.92 0.13 (0.37)
Y2.A.EN 62.72 0.286 6.83 1.9 0.24 74.6 0.263 6.44 1.6 0.10 1.19 0.92 0.94 (0.30) (0.14)
Y2.A.L 60.88 0.285 6.93 2.07 0.27 73.6 0.262 6.61 1.71 0.08 1.21 0.92 0.95 (0.36) (0.19)
Y2.B.EN 55.54 0.295 6.83 2.41 0.09 58.2 0.299 6.79 2.53 0.04 1.05 1.01 0.99 0.12 (0.05)
Y2.B.L 54.55 0.294 6.91 2.5 0.16 58.0 0.296 6.79 2.58 0.02 1.06 1.01 0.98 0.08 (0.14)
Y2.C.EN 63.41 0.286 6.92 1.93 0.21 64.7 0.288 6.74 2.21 0.07 1.02 1.01 0.97 0.28 (0.14)
Y2.C.L 59.82 0.288 6.96 2.33 0.16 62.7 0.287 6.78 2.37 0.07 1.05 0.99 0.97 0.04 (0.09)
Y2.D.EN 72.22 0.261 6.74 1.29 0.29 78.7 0.245 6.39 1.14 0.17 1.09 0.94 0.95 (0.15) (0.12)
Y2.D.L 71.7 0.254 6.80 1.33 0.29 80.1 0.241 6.57 1.17 0.16 1.12 0.95 0.97 (0.16) (0.13)
Y2.EN 81.91 0.235 6.86 0.68 0.52 85.7 0.221 6.05 0.6 0.18 1.05 0.94 0.88 (0.08) (0.34)
Y2.L 81.47 0.226 6.90 0.65 0.56 85.4 0.217 6.34 0.74 0.18 1.05 0.96 0.92 0.09 (0.38)
Y3.A.EN 70.91 0.265 6.85 1.54 0.26 64.5 0.285 6.69 2.16 0.05 0.91 1.07 0.98 0.62 (0.21)
Y3.A.L 72.22 0.259 6.91 1.59 0.26 59.9 0.288 6.86 2.42 0.04 0.83 1.11 0.99 0.83 (0.22)
Y3.B.EN 62.03 0.281 6.86 2.01 0.23 51.1 0.306 6.85 2.79 0.06 0.82 1.09 1.00 0.78 (0.17)
Y3.B.L 61.08 0.282 6.88 2.08 0.22 50.1 0.307 6.90 2.91 0.05 0.82 1.09 1.00 0.83 (0.17)
Y3.C.EN 70.4 0.268 6.89 1.54 0.26 56.7 0.299 6.80 2.6 0.02 0.81 1.12 0.99 1.06 (0.24)
Y3.C.L 67.95 0.262 6.94 1.7 0.26 56.6 0.299 6.86 2.67 0.02 0.83 1.14 0.99 0.97 (0.24)
Y3.D.EN 78.36 0.238 6.65 0.9 0.33 61.7 0.281 6.64 2.02 0.04 0.79 1.18 1.00 1.12 (0.29)
Y3.D.L 77.82 0.233 6.76 0.86 0.38 62.1 0.282 6.76 2.14 0.06 0.80 1.21 1.00 1.28 (0.32)
Y3.EN 85.7 0.216 6.75 0.41 0.59 78.8 0.242 6.24 1.2 0.13 0.92 1.12 0.92 0.79 (0.46)




Table A5.3 Subgroup analysis simulation study results (N=100) 
 
  
N=100 Independent covariates Correlated covariates Ratios: Corr::Indpndt Diff: Corr-Indpndt
PCD MSE Corr0 Incorr0 Exact PCD MSE Corr0 Incorr0 Exact PCD MSE Corr0 Incorr0 Exact
Y1.A.EN 61.69 0.293 6.70 2.22 0.11 54.0 0.303 6.53 2.51 0.01 0.88 1.03 0.97 0.29 (0.10)
Y1.A.L 61.53 0.288 6.73 2.25 0.12 55.0 0.300 6.70 2.59 0.03 0.89 1.04 1.00 0.34 (0.09)
Y1.B.EN 52.75 0.308 6.76 2.73 0.10 41.2 0.324 6.78 3.2 0.02 0.78 1.05 1.00 0.47 (0.08)
Y1.B.L 52.08 0.305 6.80 2.73 0.08 39.1 0.326 6.81 3.35 0.01 0.75 1.07 1.00 0.62 (0.07)
Y1.C.EN 57.51 0.293 6.85 2.29 0.13 48.4 0.312 6.70 2.84 0.02 0.84 1.06 0.98 0.55 (0.11)
Y1.C.L 58.8 0.292 6.86 2.34 0.09 46.2 0.309 6.78 2.91 0.02 0.79 1.06 0.99 0.57 (0.07)
Y1.D.EN 65.07 0.281 6.62 1.9 0.11 48.5 0.310 6.78 2.83 0.04 0.75 1.10 1.02 0.93 (0.07)
Y1.D.L 64.77 0.276 6.60 1.87 0.15 49.6 0.304 6.81 2.75 0.05 0.77 1.10 1.03 0.88 (0.10)
Y1.EN 81.74 0.241 6.37 0.61 0.33 79.0 0.258 6.15 1.12 0.13 0.97 1.07 0.97 0.51 (0.20)
Y1.L 81.9 0.235 6.52 0.62 0.41 78.0 0.255 6.36 1.34 0.09 0.95 1.08 0.98 0.72 (0.32)
Y2.A.EN 36.72 0.330 6.89 3.51 0.02 40.3 0.319 6.71 3.18 0.01 1.10 0.96 0.97 (0.33) (0.01)
Y2.A.L 36.34 0.332 6.95 3.56 0.02 40.0 0.318 6.73 3.22 0.00 1.10 0.96 0.97 (0.34) (0.02)
Y2.B.EN 32.39 0.335 6.93 3.65 0.03 30.2 0.336 6.88 3.68 0.00 0.93 1.00 0.99 0.03 (0.03)
Y2.B.L 31.14 0.335 6.92 3.73 0.00 30.2 0.336 6.91 3.74 0.00 0.97 1.00 1.00 0.01 0.00
Y2.C.EN 34.17 0.333 6.96 3.59 0.02 35.5 0.329 6.83 3.48 0.01 1.04 0.99 0.98 (0.11) (0.01)
Y2.C.L 34.99 0.330 6.96 3.54 0.03 35.2 0.327 6.86 3.47 0.00 1.01 0.99 0.99 (0.07) (0.03)
Y2.D.EN 41.98 0.320 6.82 3.27 0.01 43.8 0.319 6.67 3.06 0.03 1.04 1.00 0.98 (0.21) 0.02
Y2.D.L 40.9 0.321 6.87 3.33 0.02 40.7 0.322 6.71 3.24 0.01 1.00 1.00 0.98 (0.09) (0.01)
Y2.EN 48.62 0.313 6.79 2.78 0.06 63.7 0.293 6.44 2.19 0.02 1.31 0.94 0.95 (0.59) (0.04)
Y2.L 49.55 0.310 6.79 2.79 0.06 60.1 0.293 6.54 2.32 0.02 1.21 0.94 0.96 (0.47) (0.04)
Y3.A.EN 37.21 0.329 6.87 3.39 0.05 38.2 0.320 6.64 3.33 0.00 1.03 0.97 0.97 (0.06) (0.05)
Y3.A.L 37.22 0.326 6.92 3.4 0.05 37.2 0.319 6.73 3.41 0.01 1.00 0.98 0.97 0.01 (0.04)
Y3.B.EN 34.66 0.327 6.80 3.46 0.04 28.1 0.340 6.92 3.77 0.00 0.81 1.04 1.02 0.31 (0.04)
Y3.B.L 33.36 0.328 6.91 3.54 0.03 26.7 0.339 6.90 3.83 0.00 0.80 1.03 1.00 0.29 (0.03)
Y3.C.EN 34.98 0.332 6.95 3.56 0.04 30.6 0.338 6.92 3.72 0.00 0.87 1.02 1.00 0.16 (0.04)
Y3.C.L 35.24 0.330 6.95 3.52 0.06 30.7 0.339 6.96 3.73 0.00 0.87 1.03 1.00 0.21 (0.06)
Y3.D.EN 41.81 0.323 6.86 3.2 0.02 31.1 0.331 6.79 3.51 0.01 0.74 1.02 0.99 0.31 (0.01)
Y3.D.L 39.51 0.323 6.86 3.29 0.03 33.4 0.326 6.79 3.44 0.00 0.85 1.01 0.99 0.15 (0.03)
Y3.EN 51.59 0.303 6.73 2.56 0.09 50.2 0.314 6.85 2.75 0.04 0.97 1.04 1.02 0.19 (0.05)
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